Natural Bioactive Compounds Targeting Histone Deacetylases in Human Cancers: Recent Updates

Abdelhakim Bouyahya 1,* 5, Naoufal El Hachlafi 2, Tarik Aanniz 1, Hamme Mechchate 4, 9, Taoufiq Benali 3, Mohammad Ali Shariati 6, Pavel Burkov 7, José M. Lorenzo 8, 9, 10, Polrat Wilairatana 10, 11, 12, Mohammad S. Mubarak 11, 12, Ilhame Bourais 1, Ilhame Mechchate 4, and Nasreddine El Omari 12

Abstract: Cancer is a complex pathology that causes a large number of deaths worldwide. Several risk factors are involved in tumor transformation, including epigenetic factors. These factors are a set of changes that do not affect the DNA sequence, while modifying the gene’s expression. Histone modification is an essential mark in maintaining cellular memory and, therefore, loss of this mark can lead to tumor transformation. As these epigenetic changes are reversible, the use of molecules that can restore the functions of the enzymes responsible for the changes is therapeutically necessary. Natural molecules, mainly those isolated from medicinal plants, have demonstrated significant inhibitory properties against enzymes related to histone modifications, particularly histone deacetylases (HDACs). Flavonoids, terpenoids, phenolic acids, and alkaloids exert significant inhibitory effects against HDAC and exhibit promising epi-drug properties. This suggests that epi-drugs against HDAC could prevent and treat various human cancers. Accordingly, the present study aimed to evaluate the pharmacodynamic action of different natural compounds extracted from medicinal plants against the enzymatic activity of HDAC.

Keywords: epigenetic; histone deacetylases; cancer; natural compounds; epidrugs
1. Introduction

Cancer is a group of pathologies with severe consequences for human health. It is induced by numerous risk factors, such as genetic predisposition, hormonal disorders, oxidative stress, epigenetic instability, microbial infections, and many others [1]. Recently, close correlations between loss of cellular memory, epigenetic instability, and the onset of certain cancers have been demonstrated [2]. In this respect, epigenetic modifications are biochemical marks deposited on DNA and histones, and they participate in the regulation of gene expression at the transcriptional level. These modifications have several roles, including maintaining cell memory during mitotic division; differentiated cells must retain their cellular memory to keep their identity. However, cells can lose their memory and become cancerous due to epigenetic instability. HDACs play a key role in maintaining repressive gene activity. The repressive activity of HDAC leads to the ectopic repression of various genes, which can affect cellular memory. In addition, normal cells can become cancerous after transformation.

The United States Food and Drug Administration (FDA) has approved four HDAC inhibitors as anti-cancer drugs: Vorinostat, Romidepsin, Belinostat, and Panobinostat. In this respect, Vorinostat (Zolinza®) was the first histone HDAC inhibitor approved by the FDA in 2006 to treat advanced and refractory cutaneous T-cell lymphoma (CTCL) [3]. Vorinostat binds to the active sites of histone deacetylases and acts as a chelator of zinc ions at the bottom of the HDAC’s catalytic domain. It causes chromatin decondensation by inhibiting the suppression of acetyl moieties from the ε-amino groups of the lysine residues of histones and transcription factors [4,5]. It, additionally, has a 30% response rate, as revealed by clinical studies [6]. In November 2009, Romidepsin (Istodax®), a second HDAC inhibitor, was approved by the FDA for CTCL, with an overall response rate of 34%, and it was later approved for peripheral T-cell lymphoma (PTCL) [6]. According to published research, Vorinostat inhibits the deacetylation of key autophagic markers and interferes with autophagic cell death, which can be an associated mechanism, depending on the involvement of apoptosis [7]. In July 2014, the FDA approved Belinostat (Beleodaq®) as a third HDAC inhibitor, to treat patients with relapsed or refractory PTCL, and which has an overall response rate of 25.8% [8]. Another HDAC inhibitor is Panobinostat (Farydak®), which was approved in February 2015, to treat multiple myeloma [9]. Furthermore, other HDAC inhibitors, Valproic acid and Entinostat, are in phase III of a clinical trial for use against solid tumors and hormone-receptor-positive advanced breast cancer [10].

Recent investigations revealed that inhibition of HDAC-like enzymes could prevent and treat different types of cancer at the molecular level, by restoring cellular memory. Within this context, specific secondary metabolites extracted from herbs, including terpenoids, phenolic acids, flavonoids, and alkaloids, have shown inhibitory effects against HDAC [11–14]. These compounds can act specifically, either against the action of HDAC, or against the signaling pathways induced by HDAC [15,16]. Based on the preceding discussion, this review focuses on the close relationship between epigenetic modifications, particularly HDAC enzymes, and tumor transformation. Thus, the pharmacodynamic action of different natural molecules extracted from medicinal plants against the enzymatic activity of HDAC is discussed, to suggest an innovative therapy implementing the maintenance of cellular memory using anti-HDAC epi-drugs.

2. Epigenetic Regulation and Cancer

The involvement of environmental, lifestyle, and hereditary factors is the origin of the complexity of cancer etiology. Cancer is most commonly considered a genetic pathology induced by gene expression alteration, following repetitive genetic aberrations. Currently, it is known that the disruption of gene expression causing cell transformation is controlled by epigenetics. Thus, the abnormality of epigenetic regulation has become a model to explain carcinogenesis and cancer development. Research findings suggest that genetic and epigenetic mechanisms are not separate events in cancer, but interact and benefit from each other during tumorigenesis [17,18]. Epigenetic changes are labeled as ‘first hits’ for
tumorigeneses. They are the early events responsible for the loss of tissular homeostasis and induce genetic instability; thus, causing changes in the expression profile of tumor-suppressor genes. Furthermore, it is evident that several tumor suppressor genes are rarely genetically mutated but epigenetically silenced [19].

Epigenetic events include histone modifications (phosphorylation, acetylation, methylation, SUMOylation, and ubiquitylation), DNA methylation, and deregulation of non-coding RNAs and their interactions with proteins or nucleic acids [20]. The dynamic regulation of histone marks, DNA, and chromatin structure is dynamically performed by four types of epigenetic regulators, including (i) writers, (ii) erasers, (iii) readers, and (iv) remodelers [21]. Deregulation and mutations in the genes encoding these epigenetic regulators have been described in various cancers [22].

2.1. Cancer and DNA Methylation

DNA methylation consisting of a covalent transfer is the most commonly studied epigenetic modification by DNA methyltransferases (DNMTs) of methyl groups at the fifth carbon of cytosine (5-mC) within 5′-CpG-3′ di-nucleotides [23,24]. In mammals, DNMT1, DNMT3a, and DNMT3b are the three main classes of DNMT enzymes. In this regard, abnormal DNA methylation patterns are due to DNMT overexpression or aberrant recruitement. Cancer cells exhibit abnormal DNA methylation patterns, marked by global hypomethylation associated with the promoter and focal hypermethylation of specific genes [25,26]. In addition, aberrant hypomethylation induces the expression of numerous genes, including oncogenes [27], whereas hypermethylation inhibits specific tumor suppressor genes (TSGs) [28]. On the other hand, hypomethylation of oncogenesis is often revealed in cancers such as SLC34A2 in papillary thyroid carcinoma, LY6K in glioblastoma, and RBBP6 in colorectal cancer, among others [29–31].

Moreover, hypermethylation is easily observed at precancerous stages in benign tumors and tumor-predisposing inflammatory lesions [32,33]. In this respect, the retinoblastoma gene’s hypermethylation of the CpG island promoter is released in retinoblastoma [34]. Several research studies have shown promoter hypermethylation and silencing of other TSGs in renal cancer; VHL (von Hippel–Lindau) [35] in bladder cancer; the cell cycle regulator CDKN2A/p16 [36]; and in colon cancer, the mismatch repair gene hMLH1 [37]. Additionally, abundant hypermethylated TSGs include RASSF10 and SIX3 in kidney cancer and glioblastoma, respectively [38,39]; PTEN, and CDKN2A in melanoma [40,41]; and CDKN2A, TIMPS, and DAPK in prostate cancer [42]. In contrast, significant methylation of EN1 and SCTR was observed in the prostate, colorectal, and salivary gland adenoid cystic carcinoma [43]. The gene APC is hypermethylated in pancreatic cancer [44]. Indeed, hMLH1 still carries a genetic mutation and hypermethylation of an allele in the colon cancer cell line HCT116, which induces the inactivation of the main tumor suppressors [45]. Moreover, pax6, p16, and p15 are generally aberrantly methylated in bladder cancer [46].

2.2. Oncohistones and Histone Changes

Histone mutations play an important role in cancer epigenetics, where recurrent mutations targeting histone genes have been described in several types of cancer. Genes coding for histones are mostly mutated in cancer and are commonly named ‘oncohistones’ [47]. Mutations affecting all canonical histone classes and non-canonical histones have been recorded in different tumors [47]. H2A and H2B mutations occur in carcinomasomas, while H1 mutations were detected in diffuse large B cell lymphomas [47,48]. Similarly, mutations in H3 and its non-canonical counterpart H3.3 were seen in children’s tumors [49,50], whereas mutations in osteosarcoma and giant cell tumor of bone harbor H3.3 G34W mutations [51,52].

Histone modifications control chromatin’s active and inactive states, which ultimately affect gene expression [53]. Important roles are attributed to certain histone modifications in epigenetic acetylation, methylation, and deregulation; linked to epigenetic abnormalities in cancer cells [54,55]. In core histones, H3 and H4, methylation of specific residues and loss
of acetylation have been defined as a marker of cancer cells [54,55]. Enzymes that modulate histone modification include histone demethylase (HDMT), histone methyltransferase (HMT), E3-ubiquitin and kinases, histone acetyltransferase (HAT), and histone deacetylase (HDAC) [56].

2.2.1. Histone Methylation and Cancer

Histone methylation affects the affinity of transcription factors, leading to activation or restriction of transcription. Irregularities in the methylation of different lysine residues can modify gene expression [57]. In general, H3K4, H3K36, and H3K79 are the most important sites where their methylation causes gene transcription, while methylation of H3K27, H4K20, and H3K9 is related to transcription silencing [58]. In addition, trimethylations of H3K79, H3K27, and H3K9 induce repression, while mono-methylations of H4K20, H3K27, H3K9, H2BK5, and H3K79 induce gene expression.

H3K27M has been detected in 20% of pediatric glioblastomas and up to 70% of diffuse intrinsic pontine gliomas (DIPGs), resulting in decreased trimethylation of H3K27 (H3K27me3) [50,59–61]. Degradation of the EZH2-induced methylation of H3K27 has been reported in breast, prostate, bladder, lung, and kidney cancers and hematological malignancies [62]. Meanwhile, the H3K36M mutation induces undifferentiated sarcoma, causing increased levels of H3K27me3 and global loss of H3K36 (me2 and me) [63,64]. In this regard, H3K27ac enrichment and interactions with other regulatory constituents are promoted by H3K36me2 expansion favors, thus, activating oncogenic pathways [65]. Moreover, increased H3K4me3 is observed in myeloid and lymphoid leukemias [66].

2.2.2. Histone Acetylation/Deacetylation and Cancer

Histone acetylation and deacetylation are correlated with the active and open chromatin conformation and inactive and condensed chromatin form, respectively. In this respect, the HDAC and HAT enzymes control the regulation of histone acetylation, which is very dynamic [67]. The acetyl-CoA acetyl group was added, by HAT, to the histone at the lysine position, which neutralizes the positive lysine charge disrupting the electrostatic interaction between DNA and histones. The chromatin structure was attenuated; thus, affecting the gene assembly and changing the transcription operation [68].

An imbalance of histone acetylation was detected in lung cancers, Rubinstein–Taybi syndrome, AML, and glioblastomas [69]. Many members of HATs mutate differently in tumors [70–72] and participate in different stages of its development, including B-cell non-Hodgkin lymphoma and leukemia [73], and have also been described in solid cancers [74,75]. Furthermore, chromosomal translocations implying HATs and their fusion proteins were involved in the onset and development of acute leukemia [76]. Moreover, any disturbance in the expression of distinct HDAC isoforms induces different cancers. Indeed, dysregulation of HDAC proteins causes aberrant deacetylation and inhibition of TSGs. HDACs can also regulate gene transcription via deacetylating the DNMT, HAT, and HDAC proteins responsible for epigenetic events [77].

2.2.3. Phosphorylation, Ubiquitination, SUMOylation, and Cancer

Abnormalities in kinase activity lead to a variety of cancers [78,79]. The decreased activity of E3 ubiquitin ligase caused by specific mutations can be the origin of various tumors, such as breast cancer and renal cell carcinoma. Moreover, cervical cancer is caused by an increase in the ubiquitination effect, while glioblastoma and colorectal cancer are induced by the total elimination of ubiquitination [80]. SUMOylation is a process required for all cells, and not as a tumor promoter and suppressor [81].

2.2.4. Epigenetic Regulation by miRNAs and Cancer

Epigenetic linked noncoding RNAs (ncRNAs) comprise small interfering RNA (siRNAs), long noncoding RNAs (lncRNAs), microRNAs (miRNAs), and Piwi-interacting RNA (piRNAs). In this regard, ncRNAs are involved in complex double-negative feedback loops, where
miRNA inhibition of an epigenetic regulator is performed at the epigenetic level by the same regulator. In contrast, the epigenetic modifier enzymes involved in epigenetic modulation can be targeted by miRNAs, establishing a trilateral regulatory ‘epi–miR–epi’ feedback circuit. The intricate interaction between the epigenetic architecture and miRNAs is important to surveilling gene expression profiles in cancer [82]. They have been classified as tumor suppressors, oncogenic, or context-dependent miRNAs [83]. Furthermore, miRNAs regulate the expression of epigenetic regulatory enzymes, such as HMT, DNMT, and HAT. Moreover, aberrant miRNA profiling indicative of altered regulatory factors, including cell migration and proliferation, has been reported in numerous tumors, with the most manifest being the decreased ncRNA expression levels in cancer cells compared to normal tissues [84].

To date, many aberrant miRNAs have been reported in almost all cancer classes. The first cancer-associated miRNAs were miR-16 and miR-15 in B-cell leukemia [85]. In fact, miR-15-16 and miR-146 are downregulated in cancers, while putative onco-miRNAs such as miR-155, miR-210, miR-221, miR-21, and miR-17-92 are usually upregulated; conferring advantageous traits by targeting TSGs [86]. Additionally, miR-101 and miR-29 target epigenetic modifiers such as EZH2 [87,88] and DNMT3A/B [89], respectively, whereas miR-9 hypermethylation is observed in breast, colon, and pancreas cancers, as well as in acute lymphoblastic leukemia [90–92]. The miR-127, which targets BCL6, is negatively methylated and silenced in cancer [93]. On the other hand, the miR-181 family displays inconsistent expression in numerous solid cancers, showing that it could be onco-miRNAs and tumor suppressor miRNAs [94]. Other miRNAs often hypermethylated include miR-92 and miR-29b, which act as oncogenic miRNAs, inducting reactivation of silenced oncogenes [95–97].

3. The Role of HDAC in Cancer

In many human cancers, dysregulation of epigenetic enzymes results from mutations, abnormal expression, and/or disproportionate recruitment to certain loci. Histone acetylation modulates the chromatin structure, which is a key factor regulating gene expression. Histone acetylation is due to the well-balanced activities of HATs and HDACs. Indeed, HDACs remove the acetyl moiety from lysine residues, resulting in positively charged histones. This increases the ionic interactions with DNA that provoke a compacted chromatin structure, which represses gene expression by making it difficult to access the transcription machinery. Moreover, in the absence of a signal, HDACs can form a corepressor complex with the nuclear receptor and interact directly with transcription factors (Figure 1) [98].

![Figure 1](image)

Figure 1. The catalytic action of HDAC enzymes on chromatin condensation.

So far, 18 mammalian HDACs have been described and assembled into four families according to their homology with yeast HDACs [99,100]. Homologous to yeast Rpd3, Class I HDACs (1, 2, 3, and 8) are localized in the nucleus of human cells. Class II HDACs (4, 5, 6, 7, 9, and 10) are homologous to yeast Hda1, exhibit a tissue-specific expression, and can shift between the nucleus and cytoplasm. Class III HDACs, or sirtuins (SIRT1-7), are homologous to yeast Sir2 and require the NAD+ cofactor for their activity. Finally, Class IV HDACs, including the recently discovered HDAC11, display the characteristics of both Class I HDACs and HDAC II [99,100].

The implications of HDACs in cancer development were first reported in hematological malignancies by inappropriate involvement of HDAC-containing complexes [100,101].
Until now, very rare mutations altering HDAC expression and activity have been recorded in tumors, while deregulation of their activity has been associated with abnormal gene expression and carcinogenesis. Many studies reported that HDAC1 is overexpressed in prostate, colon adenocarcinoma gastric, and breast carcinomas [102–105], whereas HDAC2 is overexpressed in colorectal [106], cervical [107], and gastric cancers [108]. Overexpression of HDAC1, HDAC2, and HDAC3 is linked to low survival in patients with gastric and ovarian cancers, while HDAC6 was highly expressed in breast cancer specimens [109]. HDAC8 overexpression was reported in neuroblastoma, whereas low HDAC4 levels are reported in gastric cancers [110,111].

Research findings indicated that knockdown of HDAC genes induced apoptosis and cell cycle arrest, particularly HDAC 1, 2, 3, and 6, in various cancers (colon, breast, lung, and acute promyelocytic leukemia (APL)) [103,111–115]. Knockdown of the HDAC4 gene inhibited cell proliferation and induced apoptosis [116]. Class II HDACs are also involved in angiogenesis regulation, as the knockdown of HDAC6 and HDAC10 reduced angiogenesis-associated VEGFR1 and VEGFR2 [117]. Many reports showed up- or downregulation of SIRT genes in tumors. Along this line, SIRT1 was upregulated in lung cancer [118], prostate cancer [119], and leukemia [59], and downregulated in colon tumors [120]. Embryonic lethality, ascribed to reduced ability to repair DNA damage, was observed in mice lacking SIRT1 [121–123]. High levels of SIRT1 in AR-positive prostate cancer cell lines repress their multiplication. Indeed, SIRT1 can elicit senescence and avoid tumorigenesis [124]. SIRT2 is frequently downregulated in human gliomas [124–126].

3.1. HDAC in Different Cancer Stages

During cancer development, many factors, including inhibition of apoptosis and differentiation, and the promotion of proliferation, angiogenesis, and metastasis are epigenetically regulated. Here, we tried to associate the deregulation of HDACs with different steps of tumor development.

3.1.1. Cell Cycle Progression and Apoptosis

Several HDACs (from 1 to 6) are involved in tumor development, and their loss promotes cell proliferation dysregulation [113,116,127–129]. HDAC1 reduces suppressors of the cell cycle mutually with Rb and by altering E2F1 activity [130]. The inhibition of HDAC 1-2 induces cell cycle arrest [131]. HDAC1 is also involved in G1/S and G2/M transitions. Another study also showed that HDAC1 knock-down contributes to G2/M phase arrest [132]. Similarly, both HDAC3 and HDAC10 modulate the G2/M transition [133,134]. High levels of Sp1 due to HDAC1/2/6 activities promote the division of cancer cells and G2/M progression [135]. Knockdown of HDAC5 induced gathering of cells at the G2/M phase [103], whereas in osteosarcoma cells, this effect causes siRNA-mediated HDAC1 depletion [129].

Cell cycle interruption at the G2/M stage in renal cancer, following the inhibition of HDAC6 and HDAC3, has been ascribed to proteasomal alteration of Aurora B and A [136]. Furthermore, SIRT1 can suppress the cell cycle through the blockage of p53-dependent pathways [137]. HDAC11 negatively affects E2F7, E2F8, and cell cycle suppressors, leading to survival of tumor cells [138]. Moreover, HDACs act as apoptosis regulators, as the interruption of this process is a critical factor for tumor progression and, therefore, is considered a hallmark of tumor progression. HDACs contribute to the extrinsic, as well as intrinsic, apoptotic pathways. Regarding the extrinsic apoptotic pathways, HDACs can obstruct TRAIL or TGF-b-mediated pathways, while pro- and antiapoptotic factors are altered in the intrinsic pathway [139].

3.1.2. Differentiation

During differentiation, establishing a specific gene expression profile is harmonized by epigenetic modifications, e.g., histone acetylation. In this context, HDAC3 was recruited by RARPMML [140], while HDAC4 interacted with RAR-PLZF [141] to repress differentiation-specific transcription. A close mechanism of retinoic acid signaling limi-
tation in hematopoietic cells was recorded in AML1-ETO fusion proteins, which bind to HDAC1, 2, and 3 [142,143]. HDAC8 is a key regulator of cancer cell differentiation [144], and HDAC8 overexpression is associated with neuroblastoma progression.

3.1.3. DNA Damage Response

HDACs contribute to DNA damage repair (DDR) responses via their key role in remodeling chromatin and regulating the acetylation patterns of proteins associated with DNA [145]. The inhibition of HDAC blocks double-strand break (DSB) repair and radiosensitizes cancerous cells. In this line, HDAC2 and HDAC1 bind to DNA damage regions, to deacetylate histones at H3K56 and H4K16 and promote non-homologous end-joining pathways, which accelerate DSB repair [146]. Moreover, HDAC3 is involved in nucleotide excision repair (NER) [147], whereas HDAC9 and HDAC10 contribute to homologous recombination [148,149]. HDAC6, in association with DNA mismatch repair protein (MSH2), acts as an MSH2 inhibitor through deacetylation and ubiquitination [150]. In addition, Sirtuins interact with numerous proteins regulating several DDR pathways [151]. In tumor cells, SIRT1 restraints p53 acetylation, contributing to cell survival [148,152]. SIRT6 phosphorylation is directly engaged in DNA damage sites to promote DSB repair [153,154]. In leukemia-initiating cells, the inhibition of SIRT6 or HDAC8 engenders a DNA repair deficit in homologous recombination and the NHEJ pathway [155].

3.1.4. Metastasis

The capacity to disperse and metastasize represents the deadliest signature of tumor cells. Numerous works have evidenced that HDACs regulate metastasis in various cancers. An important player in metastasis is the transition from adherent epithelial cells to motile mesenchymal cells capable of leaving the primary tumor site. In embryonic development, EMT is a crucial path for cell migration during gastrulation [156]. In colorectal cancer, HDAC3 was engaged to Runx 2 promoter and hampered metastasis [157]. Research findings showed that HDAC7 enhances EphA2 expression by downregulating miR-4465 expression, positively affecting tumor proliferation, spread, and invasion in nasopharyngeal cancer [158]. Similarly, HDAC11 leads to the overexpression of RRM2, a gene involved in promigratory and metastatic phenotypes [138]. In prostate cancer, ZEB1 and SIRT1 together bind to CDH1, promoting metastasis [159], while SIRT1 elicited EMT through Fra-1 over-expression in colorectal cancer [160].

Nonetheless, SIRT1 seems to limit metastasis, not only via deacetylation of Smad4, but also via repression of TGF-b-triggered signaling, whereas SIRT2 deacetylated Slug and stabilized its protein to increase EMT [161]. Many metastasis repressors, such as RECK, Kangai 1, RhoB, and TIMP-1, increased their level in response to HDAC inhibitors, indicating a potential role of HDACs in the promotion of metastasis [162]. In addition, HDAC1 impaired the expression of RECK and RhoB in cancer cells [163]. EMT is promoted by transcription factors of the SNAI1/SLUG family, mediating the silencing of E-Cadherin expression by engaging the SIN3/HDAC1/HDAC2 corepressor complex and upregulating the matrix metalloproteinase family proteins. Furthermore, SNAI1, by interacting with HDAC1-2, inhibits the E-Cadherin promoter, since the addition of trichostatin A (TSA) obstructs the effect of SNAI1 in SNAI1-expressing epithelial cells [164]. The pivotal role of SNAI1 in association with HDAC1/HDAC2 and resulting in E-Cadherin repression in cancers has been documented [165].

3.1.5. Angiogenesis

Angiogenesis involves the creation and addition of new blood vessels and is pivotal for the development of tumors [166,167]. The first steps of angiogenesis are elicited by hypoxia or a hypoxic microenvironment, while its advancement is mainly controlled by hypoxia-inducible factor 1a (HIF-1a). Overall, HDACs monitor the balance between pro- and anti-angiogenic proteins. In this context, HDAC inhibition exerts anti-angiogenic activity via inhibition of pro-angiogenic gene expression. Under hypoxia conditions,
Class I HDACs, mRNA, and protein were overexpressed in vitro in primary and malignant cells [168]. HDAC1 deacetylates HIF-1α, contributing to preventing HIF-1α loss. On the other hand, dysregulated levels of HDAC1 lead to high levels of HIF-1α and VEGF in tumors, which in turn enhances angiogenesis [169]. HDAC4, 6, 10, and SIRTs display similar pathways [139], whereas HDAC4, 5, and 6, acting as mediators of HIF-1 activity, require cofactors (HSP90 and p300) [170]. On the contrary, it was shown that SIRT1 deacetylated HIF-1α, which reduces the interaction of HIF-1α with p300, which reduces HIF-1α activity. In endothelial cells, HDAC5 reduced the expression of pro-angiogenic genes (FGF2 and Slit2) [171]. Additionally, HDAC5 represses cysteine-rich angiogenic inducer 61 (CYR-61), a well-known antifibrotic and pro-angiogenic mediator, inhibiting angiogenesis [172]. HDAC6 enhances angiogenesis via deacetylation of cortactin, an actin-remodeling protein [173].

3.1.6. Autophagy

Autophagy is a process that suppresses damaged subcellular fractions, helping to intercept the transformation of normal cells to cancerous ones [174,175]. Published data showed that Class I HDACs mediate autophagic flux in mice [50], whereas elimination of HDAC1 and HDAC2 impedes autophagic flux [176]. On the other hand, HDAC4 and HDAC5 influence autophagic flux by acting as positive regulators of tumor cell development. HDAC6 promotes autophagy, based on its connection with microtubule proteins [177,178]. In this regard, autophagy might be actively enhanced and play a compensatory role for HDAC6 under ubiquitin-proteasome system damage [120,148]. At the same time, HDAC6 shows a significant role in ubiquitin-selective quality control autophagy, instead of starvation-induced autophagy [163]. Similarly, Parkin-mediated mitochondrial ubiquitination could engage the autophagic actors, i.e., HDAC6 and p62 [179]. HDAC10 knock-down induces autophagosome/lysosome fusion blockade and restriction of autophagic flux, which sensitizes cells to chemotherapy [180]. HDAC10 also deacetylates HSP70 protein members associated with autophagy-mediated cell longevity [180]. In contrast, SIRT1 displays a dual role in autophagy [181], where it is necessary to trigger starvation-induced autophagy [127,182]. Moreover, SIRT1 deacetylates forkhead box O3 (FOXO3), leading to proteasomal degradation and, thus, contributing to the overexpression of numerous autophagic genes.

In embryonic stem cells (ESCs), SIRT1 affects the PI3K/Bcl-2 and mTOR pathways, affecting oxidative stress-induced autophagy [183]. SIRT2 detaches from FOXO1 under stress conditions, which promotes hyperacetylated FOXO1, promoting the autophagic process [184]. In contrast, deacetylation of lactate dehydrogenase B (LDHB) by SIRT5 intensifies its effect. Protons (H+), generated by LDHB, promote autophagy in tumor cells [181,185]. Furthermore, SIRT5 is involved in ammonia-induced autophagy, via glutamine metabolism remodeling [184]. SIRT6 promotes autophagy by hampering the transcriptional repressor Nkx3.2, resulting in the expression of GATA5 [186].

4. Natural Bioactive Compounds Targeting HDAC in Human Cancers

4.1. Flavonoids

4.1.1. Epigallocatechin Gallate

Epigallocatechin gallate (EGCG) (Figure 2, Table 1), a flavonoid found in green tea, exhibits potent anticancer properties, by targeting epigenetic mechanisms, especially HDAC pathways. Published research showed that EGCG reduced the expression levels of HDAC2 and HDAC3, by 50 µM to 150 µM for 48 and 72 h [187], as well as downregulating the HDAC1 protein level by approximately 50% at 100 µM [188] in human colon cancer cell lines. Treatments with EGCG (40 µmol/L) and a pro-drug EGCG (pEGCG) (20 µmol/L) induced a significant suppression in the proliferation of both MCF-7 and MDA-MB-231 breast cancer cells via epigenetic mechanisms, as it inhibited the activities of histone acetyltransferase (HAT) [189]. This compound can remodel the chromatin structures of the hTERT promoter by downregulating acetyl-histone H3 and H4, as well as acetyl-H3K9 expression levels, accompanied by chromatin alterations, leading to the binding of different hTERT
repressors, including E2F-1 and MAD1 to the hTERT regulatory region [189]. In skin cancer A431 cells, EGCG (25 µM) has been reported to induce an increase in acetylated lysine 14 and 9 (on histone H3) and acetylated lysine 12, 5, and 16 on histone H4 (H3-Lys and H4-Lys) for six days [190]. Recently, it was found that EGCG (200 µM) can increase H3K9/14ac and H3ac histone acetylation up to 8-fold compared to the reference, accompanied by concomitant hypermethylation of the active H3K4me3 (almost 2.5-fold) and the repressive H3K9me3 chromatin proteins (up to 160%), correlating with downregulation of heterochromatin binding factors such as HP1α and HP1γ [191].

Figure 2. Chemical structures of flavonoids with anticancer activity by targeting HDAC.

4.1.2. Apigenin

Apigenin (4',5,7-trihydroxyflavone) (Figure 2, Table 1) is a yellow crystalline solid flavone with several natural sources, including medicinal plants. In human prostate cancer PC-3 cells, apigenin (20–40 µM) acts as a potent HDAC inhibitor, which induces noticeable suppression of the HDAC protein activity (41% and 62%), especially HDAC1 and HDAC3 [192]. It additionally promoted global acetylation of both histone H3 (7.4- and 8.2-fold) and H4 (1.2- and 2.6-fold), as well as specifically centered the hyperacetylation of histone H3 on the p21/waf1 promoter [192]. In this context, Tseng et al. [193] demonstrated that apigenin treatment for 48 h could inhibit the HDAC activity in breast cancer cells. Moreover, molecular analysis revealed that apigenin increases the expression levels of acetylated H3, particularly in the p21WAF1/CIP1 promoter area mediated by the upregulation of p21WAF1/CIP1 transcription [193].
4.1.3. Galangin

Galangin (Figure 2, Table 1) is a natural flavonoid found in honey and in lesser galangal (Alpinia officinarum Hance.). This natural compound exhibits a promising effect against HDAC activity. Treatment with galangin for 24 h increased endogenous HDAC1-mediated deacetylation, independent of DNA methylation status, and subsequently decreased histone H3 acetylation in the BACE1 promoter regions in human neuroblastoma SH-SY5Y cells [194].

4.1.4. Genistein

Genistein (Figure 2, Table 1) is a naturally occurring isoflavone, first isolated from Genista tinctoria. This compound is known for its promising chemotherapeutic effect against several types of cancer. Genistein (5–20 μmol/L) showed, in vitro, a weak inhibitory capacity of HDAC catalytic activity (13–17%) in human esophageal squamous carcinoma cells [195]. HAT and HDAC analysis demonstrated that genistein decreases HDAC, but increases HAT activity. ChIP analysis with various antibodies showed enrichment of acetylated histones H3, H4, and H3 di- and tri-methylated lysine 4 in prostate carcinoma cell lines (LNCaP, PC3) [196]. On the other hand, using mouse models, Li and coworkers [197] reported that a diet containing 250 mg/kg genistein reduced HDAC1 expression in vivo at protein and mRNA levels. Moreover, genistein also suppressed the phosphorylation of serine ten and methylation of lysine nine at the promoter regions of various genes, such as Wnt5a, Sfrp5, and Sfrp2 [198].

4.1.5. Silibinin and Kaempferol

Silibinin (Figure 2) is a flavonolignan derived from milk thistle, Silybum marianum, and has potent anticancer properties, targeting various checkpoints, including epigenetic mechanisms such as HDAC activity. Research findings demonstrated that silibinin (10–75 μM) downregulates the levels of HDAC2 and HDAC3 proteins, as well as HDAC1, HDAC6, SET domain proteins (SETD1A, D4, D6), and lysine-specific demethylases (KDM 5B, 5C, 4A) in non-small lung cancer H1299 cells [199]. In human prostate cancer cell lines (DU145 and PC3), silibinin (25–75 μg/mL) decreased the expression levels of HDAC1-2 for 48 h in a concentration-dependent manner [200]. It also increased trimethylation levels of Lys27 on H3 (H3K27me3) [200]. On the other hand, kaempferol (5 μM) has been reported to exhibit epigenetic modification in human hepatoma HepG2, Hep3B, and HCT-116 cells by binding to human HDAC enzymes and sequentially induced hyperacetylation of the histone complex H3 [201].

4.1.6. Quercetin

Quercetin (Figure 2) can be found in medicinal plants and numerous food products. This compound possesses different biological activities, including anticancer, via various mechanisms of action. Quercetin alone, or combined with other compounds, exhibited effective epigenetic modifications. At a concentration of 100 μM, it increased the histone H3 acetylation mediated by the upregulation of FasL expression, and activated the HAT and inhibited the HDAC activities [202]. In addition, quercetin (25 and 50 μM) modulated the expression of numerous chromatin modulators after 48 h of treatment and decreased HDAC and HMT activities, including the activity of HMT-H3K9 [203]. Listed in Table 1 are the natural flavonoids targeting HDAC in human cancers.
| Molecules (Origins) | Used Models | Methods | Key Findings |
|---------------------|-------------|---------|--------------|
| (-)-Epigallocatechin-3-gallate (EGCG) (Purchased) | MCF-7 and MDA-MB-231 (Breast cancer cells) | Flow cytometry (apoptosis assay) RT-PCR and real-time PCR (Quantification of hTERT expression) DNMTs, HDACs, and HATs activity assays ChIP assay Western blot analysis | Inhibited the transcription of hTERT through epigenetic mechanisms in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 cells. Inhibited the activities of DNMT and histone acetyltransferase (HAT). Remodelled the chromatin structures of the hTERT promoter by decreasing the level of acetyl-H3, acetyl-H3K9, and acetyl-H4 in the hTERT promoter. Induced chromatin alterations that facilitated the binding of many hTERT repressors such as MAD1 and E2F-1 to the hTERT regulatory region. | [189] |
| (-)-Epigallocatechin-3-gallate (EGCG) (Purchased) | A431 (Human skin cancer) | DNA methylation assay HDAC activity assay Western blot analysis Cell lysates | Decreased global DNA methylation levels in A431 cells in a dose-dependent manner. Decreased the HDAC activity. Increased the levels of acetylated lysine 9 and 14 on histone H3 (H3-Lys 9 and 14) and acetylated lysine 5, 12, and 16 on histone H4. Re-expressed the mRNA and proteins of silenced tumor suppressor genes, p16^{INK4a} and Cip1/p21. | [190] |
| (-)-Epigallocatechin-3-gallate (EGCG) (Purchased) | HT-29 and HCT 116 (Human colon cancer cell lines) | Western blot analysis RNA extraction Real-time PCR | Reduced HDAC and DNMT protein expression. Decreased HDAC2 and HDAC3 expressions. Decreased association between UHRF1 and DNMT3. Decreased association between UHRF1 and HDAC3 in only the HCT 116 cell line. | [187] |
| (-)-Epigallocatechin-3-gallate (EGCG) (Purchased) | MCF7 and MDA MB 231 (Breast cancer cells) | RT-PCR Western blot analysis | Lowered the protein levels of DNMT1, HDAC1, and MeCP2. | [204] |
| (-)-Epigallocatechin-3-gallate (EGCG) (Purchased) | HT29 (Human colon cancer cells) | HDAC enzyme activity Western blot | Inhibited the HDAC activity in intact HT29 cells. Decreased the HDAC1 protein level. | [188] |
| (-)-Epigallocatechin-3-gallate (EGCG) (Not reported) | MCF-7 and MDA-MB-231 (Breast cancer cells) | RNA extraction RT PCR ChIP method Western blot analysis | Reduced levels of the enhancer of zeste homolog 2 (EZH2) and class I HDAC proteins. | [205] |
| (-)-Epigallocatechin-3-gallate (EGCG) (Purchased) | CRL-2577, HCT-116 and HT-29HTB-38 cells | Cell viability and apoptosis Real-time quantitative PCR HDAC activity assessment ChIP assay | Combinatorial effects of EGCG and NaB. Increased HDAC1 in RKO CRC cells. Inhibited the HDAC1, DNMT1, and survivin in all the three CRC cells tested. Affected the global DNA methylation. | [206] |
| Molecules (Origins) | Used Models     | Methods                          | Key Findings                                                                                                                                                                                                 | Ref.   |
|--------------------|----------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| (-)-Epigallocatechin-3-gallate (EGCG) (Purchased) | HeLa cells | HDAC activity assessment         | Decreased the HDAC activity time-dependently. Zn ion was taken to be the substrate-binding site of HDAC1.                                                                                                     | [207]  |
|                    |                | Bisulfite modification MS-PCR RT-PCR |                                                                                               |        |
| (-)-Epigallocatechin-3-gallate (EGCG) (Purchased) | A549/DDP cell line | Cell viability assay MTT assay RT-PCR Total HDAC activity and DNMT activity in vivo experiments | In vitro EGCG + cisplatin (DDP) treatment caused: Inhibition of DNMT and HDAC activities, reversal of hypermethylated status, and downregulation of the expression of GAS1, TIMP4, ICAM1, and WISP2 gene in A549/DDP cells. In vivo EGCG + DDP pre-treatment caused: Inhibition of tumors, a decrease in methylation levels of GAS1, TIMP4, ICAM, and WISP2, and an increase in their expression levels. | [208]  |
| (-)-Epigallocatechin-3-gallate (EGCG) (Not reported) | APL NB4 and HL-60 cells | RT-qPCR ChIP assay MSP and sequencing Western blot analysis | Downregulated the epigenetic modifiers HDAC1 and HDAC2 Downregulated the polycomb repressive complex 2 (PRC2) core components in gene and protein levels. Reduced gene-binding effect of core components of EZH2, SUZ12, and EED. | [209]  |
| (-)-Epigallocatechin-3-gallate (EGCG) (Not reported) | DUPRO and LNCaP (prostate cells) | RNA extraction RT-semi q-PCR Western blot analysis ChIP assay HDAC enzyme activity | Reduced the expression of both EZH2 enhancers and its catalytic product trimethylation of H3. Increased acetylation of histone H3K9/18. Reduced the activity of Class I HDACs, as well as EZH2 and H3K27me3 levels. | [210]  |
| (-)-Epigallocatechin-3-gallate (EGCG) (Not reported) | HMEC-1 and HUVECs cells | Cell proliferation assay RNA isolation Reverse transcription and RT-PCR Western blot analysis HDAC Activity Assay | Increased histone acetylation (H3K9/14ac, H3ac), as well as methylation of both active (H3K4me3) and repressive (H3K9me3) chromatin. Inhibited HDAC activity in both cellular and cell-free models. Altered epigenome modulator expression and activity (HDAC5 and 7, p300, CREBP, LSD1 or KMT2A). | [191]  |
| (-)-Epigallocatechin-3-gallate (EGCG) (Purchased) | Breast cancer cells | RNA extraction Protein extraction qRT-PCR Western blot analysis ChIP assay HDAC activity HMT (H3K27me3) activity | Induced changes in histone modifications. Resulted in an increased apoptosis. | [211]  |
### Table 1. Cont.

| Molecules (Origins) | Used Models | Methods | Key Findings | Ref. |
|---------------------|-------------|---------|--------------|------|
| Delphinidin (Purchased) | JB6 P+ (Mouse epidermal cells) HepG2-C8 (hepatocellular cancer cells) | Western blot Quantitative real-time PCR Bisulfite genomic sequencing | Reduced DNMTs and HDACs protein expression. | [212] |
| Apigenin (Purchased) | Human prostate cancer cell lines 22Rv1 and PC-3 (prostate cancer cells) | HDAC activity assessment RNA isolation RT-PCR and q-PCR Western blot analysis ChIP assay Tumor xenograft studies | Inhibited Class I HDACs in prostate cancer cells. Inhibited HDAC enzyme activity, particularly HDAC1 and HDAC3. Induced histone acetylation. Increased p21/waf1 protein and mRNA expression, as well as p21/waf1 mRNA expression. Reduced (in vivo) tumor development, HDAC activity, HDAC1, and HDAC3 protein expression. | [192] |
| Apigenin (Purchased) | JB6 P+ (Skin cells) | RT-PCR Western blot analysis | Reduced some HDACs (1–8) and their expression levels. | [213] |
| Apigenin (Purchased) | MDA-MB-231 (breast cancer cells) | Immunoblot analysis HDAC assay Nuclear extract preparation ChIP assay | Inhibited HDAC activity. Induced acetylation of histone H3. Increased the acetylation of histone. | [193] |
| Galangin (Purchased) | Neuroblastoma cells | Flow cytometry ELISA RT-PCR and qPCR Western blot analysis ChIP assay DNA methylation analysis | Reduced the BACE1 at mRNA and protein levels. Reduced acetylated H3 in BACE1 promoter areas by increasing endogenous HDAC1-mediated deacetylation. | [194] |
| Genistein (Purchased) | Human esophageal squamous cell carcinoma cell lines KYSE 510 and KYSE 150 cancer cells | Modification by bisulfite Methylation-specific PCR RT-PCR | Reversed DNA hypermethylation. Reactivated RARβ, p16INK4a, and MGMT in KYSE 510 cells. Reversed DNA hypermethylation and reactivated RARβ in KYSE 150 cells and prostate cancer LNCaP and PC3 cells. Activated RARβ. Inhibited the activity of HDAC. | [195] |
| Genistein (Purchased) | MCF7 and MDA MB 231 (Breast cells) | Bisulfite conversion RT-PCR Western blot | Reduced HDAC1 and MeCP2 protein levels. | [204] |
| Genistein (Purchased) | A498, ACHN, HEK-293 and HK-2 cells | RT-PCR Sodium bisulfite modification and sequencing HAT and HDAC analysis | Increased HAT activity and reduced HDAC activity. | [205] |
Table 1. Cont.

| Molecules (Origins) | Used Models | Methods | Key Findings | Ref. |
|---------------------|-------------|---------|--------------|-----|
| Genistein (Purchased) | LNCaP, PC3, and RWPE-1 (Prostate cells) | Quantitative RT-PCR Sodium bisulfite modification and sequencing ChIP analysis HAT and HDAC analysis | Increased the levels of acetylated histones 3, 4, histone three dimethylated at lysine 4, histone 3 trimethylated at lysine 4, and RNA polymerase II. Decreased DNA methyltransferase and methyl-binding domain protein 2 activity. Increased HAT activity. | [196] |
| Genistein (Purchased) | HT29 (colon cancer cells) | HDAC enzyme activity Western blot analysis | Inhibited HDAC activity in intact HT29 cells. Reduced HDAC1 protein levels. | [188] |
| Genistein (Purchased) | MCF-7, MDA-MB-231, and MDA-MB-157, HMECs cells, and two mouse models | MTT assay RT-PCR ChIP assay | Reduced the activity of HDAC, alone or in combination with TSA. Reduced binding to the ERα promoter, as well as gene expression for HDACs. Reduced HDAC1 protein and mRNA expression in both animal models studied. | [197] |
| Genistein (Purchased) | Rat colon tissues | RNA isolation qPCR analysis ChIP analysis Bisulfite sequencing | In the post-AOM phase, there was a decrease in H3Ac at the promoter of Wnt5a, Sfrp5, and Sfrp2. Repressed histone H3 lysine 9 methylation and serine 10 phosphorylation at the promoters of Sfrp2, Sfrp5, and Wnt5a in the post-AOM period. In the post-AOM period, the nuclear level of HDAC3 protein was increased. After AOM induction, H3Ac was reduced in the same region of the Sfrp5 promoter. | [198] |
| Genistein (Purchased) | MCF-7 and MDA-MB-231 cells | HDAC activity assay HMT activity | Inhibition of HDAC and HMT by GEN + SFN. Downregulation of HDAC2 and HDAC3 levels at the mRNA and protein levels. GEN + SFN downregulated the hTERT levels. | [214] |
| Genistein (Purchased) | Human cervical cancer cells | DNMT and HDAC activity analysis In silico studies in the post-AOM period | Reduced the expression of HDAC and enzymatic activity in a time-dependent manner. Interacted with members of the DNMT and HDAC families. Reversed the tumor suppressor genes’ promoter region methylation, and their expression was restored. | [215] |
| Genistein (Purchased) | HeLa cells | qPCR HDAC activity assay HMT-H3K9 activity Global DNA methylation | Altered HDACs, HMTs, demethylases, and histone phosphorylases’ expression. Reduced HDAC and HMT activity, as well as global DNA methylation levels. | [203] |
| Molecules (Origins)       | Used Models                                      | Methods                                           | Key Findings                                                                                                                                       | Ref.     |
|--------------------------|--------------------------------------------------|---------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| Kaempferol (Not reported)| HepG2, Hep3B, and HCT-116 cells                  | In silico docking analysis                        | Inhibited the activity of HDAC. Induced hyperacetylation of histone complex H3. Reduced cell viability and proliferation rate.                  | [201]    |
|                          |                                                   | HDACi screening assay                             |                                                                                                                                                    |          |
|                          |                                                   | HDAC inhibition profiling                         |                                                                                                                                                    |          |
|                          |                                                   | Immunoblotting                                    |                                                                                                                                                    |          |
|                          |                                                   | Real-time cell monitoring                         |                                                                                                                                                    |          |
| Luteolin (Purchased)    | MDA-MB231-1833, LNM35, HT29, HepG2, and MCF7/6 cells | HDAC assay and histone acetylation levels         | Inhibited HDAC activity.                                                                                                                         | [216]    |
| Luteolin (Purchased)    | HCT116 (Colorectal cells)                        | HDAC activity assay                               | Reduced levels of HDAC protein and enzyme activity.                                                                                              | [217]    |
| Pectolinarigenin (Purchased) | 143B, HOS, and MG63 (Osteosarcoma)              | Western blot analysis                            | Disrupted the development of the STAT3/DNMT1/HDAC1 complex. Caused an increase in SHP-1 expression in osteosarcoma.                           | [218]    |
| Pelargonidin (Purchased)| Skin epidermal JB6 (JB6 P+) cells               | Western blot analysis                            | Reduced protein levels of genes encoding HDACs.                                                                                                 | [219]    |
|                         |                                                   | RT-PCR                                            |                                                                                                                                                    |          |
|                         |                                                   | Bisulfite genomic sequencing                      |                                                                                                                                                    |          |
| Silibinin (Not reported)| H1299 cells                                      | HDAC activity                                    | Reduced the activity of HDAC in a dose-dependent manner. Reduced HDAC1, HDAC2, and HDAC3 protein levels, whereas HDAC1, HDAC6, SET domain proteins (SETD1A, D4, D6) and lysine-specific demethylases were upregulated (KDM 5B, 5C, 4A). | [199]    |
| Silibinin (Purchased)   | SW480 and SW620 (Colon cells)                    | HDAC activity                                    | No effect on the activity of HDACs.                                                                                                               | [220]    |
| Silibinin (Purchased)   | DU145 and PC3 (Prostate cells)                   | Western blot analysis                            | Reduced HDAC1-2 expression levels in a concentration-dependent manner.                                                                          | [200]    |
| Taxifolin (Purchased)   | HepG2 cells, skin epidermal JB6 P+ cells, and HepG2-C8 cells | Western blot analysis                            | Inhibited DNMT and HDAC protein expression.                                                                                                       | [221]    |
|                         |                                                   | RNA extraction                                    |                                                                                                                                                    |          |
|                         |                                                   | qRT-PCR assay                                     |                                                                                                                                                    |          |
|                         |                                                   | Bisulfite genomic sequencing                      |                                                                                                                                                    |          |
|                         |                                                   |                                               |                                                                                                                                                    |          |
| Quercetin (Purchased)   | HL-60 (leukemia cells)                           | Western blot analysis                            | Increased histone H3 acetylation, which promoted the production of FasL. Activated HAT and inhibited HDAC.                                      | [202]    |
| Quercetin (Purchased)   | Hamster buccal pouch (HBP) carcinomas            | Immunohistochemistry                              | Inhibited HDAC-1 and DNMT1 activities.                                                                                                           | [222]    |
|                         |                                                   | Western blot analysis                            |                                                                                                                                                    |          |
Table 1. Cont.

| Molecules (Origins) | Used Models | Methods | Key Findings | Ref. |
|---------------------|-------------|---------|--------------|-----|
| Quercetin (Purchased) | Eca9706 cells | MTT assay Immunoblotting MSP of p16\(^{INK4a}\) gene promoter | Reduced the reverse expressions of global HDAC1. Quercetin + butyrate displayed a reverse effect targeting both altered DNA methylation and histone acetylation, acting as HDAC inhibitor mediated via epigenetic-NF-κB cascade signaling. | [223] |
| Quercetin (Purchased) | HeLa cells | DNMT and HDAC activity assay HMT-H3K9 activity assay Molecular modeling qRT-PCR | Reduced the activity of HDAC activity. Reduced the activation of HMT-H3K9. Modified the expression of many chromatin modifiers, and lowered the activity of HDACs and HMTs. Several DNMTs and HDACs interacted with residues in their catalytic cavities (as a competitive inhibitor). | [203] |

4.2. Alkaloids

Alkaloids such as berberine, nicotinamide, isoistularin-3, psammaplin, and TSA (Table 2, Figure 3) exhibit promising anticancer effects via the control of epigenetic changes and various other mechanisms. The HDAC signaling pathways represent some of the main targets of these bioactive compounds. In this context, berberine (120 \(\mu\)M) exhibits remarkable anticancer effects via targeting epigenetic chromatin modification, which affects the enzyme implicated in histone acetylation and methylation in acute myeloid leukemia (AML) cell lines [224]. These events revealed the role of berberine as a master epigenetic regulator responsible for controlling downstream bioactivities, including cell cycle arrest, apoptosis, and the underlying mechanism of metabolic disorders and immune response.

Table 2. Natural alkaloids targeting HDAC in human cancers.

| Molecules (Origins) | Used Models | Methods | Key Findings | Ref. |
|---------------------|-------------|---------|--------------|-----|
| Berberine (BBR) (Purchased) | U266, KG1-\(\alpha\), and HL-60 cells | Molecular Docking Growth inhibition assessment RT-PCR Western blot analysis | Affected the enzymes involved in histone acetylation and methylation. Induced cytotoxicity and apoptosis in HL-60/ADR and KG1-\(\alpha\) cells. Upregulated histone acetyltransferase CREBBP and EP300, histone deacetylase SIRT3, histone demethylase KDM6A, as well as histone methyltransferase SETD7. Downregulated histone acetyltransferase HDAC8, histone methyltransferase WHSC1I, WHSC1II, and SMYD3. | [224] |
| Isoistularin-3 (Iso-3) (Aplysina aerophoba) | RAJI, U-937, JURKAT, K-562, HL-60, MEG-01, cells | HDAC activity assessment Molecular docking study Western blot analysis | Modified the aryl hydrocarbon receptor (AHR) promoter methylation and increased the AHR expression in RAJI cells. | [225] |
### Table 2. Cont.

| Molecules (Origins) | Used Models | Methods | Key Findings | Ref. |
|---------------------|-------------|---------|--------------|------|
| Nicotinamide (NA)   | Female mice skin | RT-PCR, DNA bisulfite modification, Western blot analysis | Downregulated the miR-203 levels at 16 weeks. Upregulated the HDAC, DNMT, and promoter methylation of miR-203 at 4 or 16 weeks. Prevented changed gene expression. | [226] |
| Trichostatin A (TSA) | PANC-1, CAPAN (1 and 2), and KATO-III cells | RT-PCR, siRNA, Western blot analysis, ChIP assay | TSA + 5-aza increased MUC4 expression in a cell-specific manner. MUC4 silencing was directly engaged by HDAC3, HDAC1, DNMT3B, and DNMT3A binding to its 5'-UTR in a cell-specific manner. Inhibited the histone deacetylation, associated with strong MUC4 repression in high-expressing cells. | [227] |
| Psammaplin (Jaspis sp. and Poecillastra wondoensis) | Ishikawa cancer cells | RT-PCR, Western blot analysis | Induced accumulation of acetylated histones and reduced HDAC levels. Upregulated cyclin-dependent kinase inhibitor expression. Inhibited HDAC1 activity. Exhibited significant cytotoxicity in A549, MCF7, and W138 cells. Increased acetylation of histones. | [228] |
| Psammaplin (Pseudoceratina purpurea) | A549, MCF7, and W138 cells | HDAC Assay, Immunoblotting | Inhibited HDAC effectively. Induced weak cytotoxicity. | [229] |
| Psammaplin (Pseudoceratina purpurea) | In vitro enzymatic assays | Cell proliferation assessment, HDAC enzyme activity | Reduced the activity of HDAC, either alone or in conjunction with GEN. | [197] |
| TSA (Purchased) | MCF-7, MDA-MB-231, and MDA-MB-157 cells and mouse models | RT-PCR assay, Western blot analysis, ChIP assay | TSA + decitabine reduced the DNMT and HDAC activities. TSA + decitabine increased acetylation of histone H3 and H4. TSA + decitabine inhibited the expression of lysine-specific demethylase-1. TSA + decitabine increased the transcription activity marker dimethylated-H3K4, while suppressing dimethylated-H3K9. | [231] |

The findings by Florean and colleagues [225] revealed that isofistularin-3, a brominated alkaloid derivative isolated from *Aplysina aerophoba*, can inhibit DNMT1 in vitro (IC_{50} = 13.5 ± 5.4 µM), through binding to the DNA-interacting pocket of the enzyme. In addition, Iso-3, at a dose of 25 µM, induced modification of the AHR promoter methylation and upregulated the AHR expression in RAJI cells. These effects are probably associated with generating an altered chromatin state via histone deacetylase activity (HDAC). These results were validated in vivo in a zebrafish xenograft model. Notably, researchers provided evidence that Iso-3 does not elicit acute toxicity in developing zebrafish, shown by the absence of morphological defects and dead embryos, even at the highest dose, after 24 h of treatment. Moreover, using a mice skin model, Tiwari and Gupta [226] found that nicotinamide (NA) treatment (5 mg) increases the expression levels of HDACs, mediated by the downregulation of tumor suppressor miR-203, at a period between 4 and 16 weeks. The combination of this molecule (NA) with 7, 12-dimethylbenz [a] anthracene, a potent carcino-
gen compound, exhibited further effects: targeting the HDAC pathway, providing a novel chemoprevention strategy by combining different compounds through the control of epigenetic and microRNA biogenesis modulators in tumor development, in a time-dependent manner [226]. Within this context, the study of Vincent et al. [227] demonstrated that TSA (0.3 µM), a hydroxamic acid first identified in the bacterium *Streptomyces platensis*, exhibits a broad-spectrum of reversible HDAC inhibitory activity. Chromatin immunoprecipitation and RNA interference assays showed that TSA inhibits the histone deacetylation concomitant with potent MUC4 repression in high-expressing cells [227]. Moreover, treatment of breast MDA-MB-231 cell lines with TSA (100 ng/mL for 12h) combined (25 µM for two days) with genistein showed promising histone changes in the estrogen receptor-α (ERα) promoter and consecutively decreased the HDAC activity [197]. The potential toxicity of this new combination has been reported in normal human mamma epithelial cells (HMECs). It has been shown that the combined treatment of TSA with genistein is potentially safe and can be applied to in vivo experiments.

In a similar fashion, Ahn and coworkers [228] reported the antiproliferative activity (IC₅₀ = 5µg/mL) of the alkaloid psammaplin A as an HDAC suppressor. They showed that this molecule exhibited remarkable epigenetic regulation and exhibited antiproliferative activity against endometrial cancer cells at the lowest dose of 5 µg/mL, triggering genes related to apoptosis and cell cycle arrest, accompanied by accumulation of acetylated histones and decreased expression levels of HADC [228]. Moreover, using human cancer cell lines, Baud et al. [229] reported the molecular and the enzymatic mechanisms of psammaplin A against its HDAC targets. These researchers showed that psammaplin A (11c) remarkably affects HDAC1 in vitro (IC₅₀ = 0.9 nM). Regarding the enzymatic specificity of psammaplin A, it has been found that this compound exhibits strong isoform selectivity, which is 360-fold selective for HDAC1 compared to HDAC6, and more than 1000-fold less effective against HDAC8 and HDAC7.

### 4.3. Terpenoids

#### 4.3.1. Corosolic Acid

Corosolic acid (Figure 4, Table 3) is a triterpene acid isolated from *Lagerstroemia speciose*. This bioactive compound is commonly abundant in food sources such as guava, loquat, and olive, and exhibits various pharmacological effects, including anti-proliferative activity. In this respect, Zhang and coworkers [232] studied the role of corosolic acid in the activity and expression of HDACs, in a transgenic adenocarcinoma mouse prostate (TRAMP) model, as well as its involvement in DNA and histone H3 methylation. These researchers found that corosolic acid promotes downregulation of the expression and activity of epigenetic modulatory proteins, demonstrating its ability to prevent prostate carcinogenesis. In addition, corosolic acid (4 µM) significantly increased the expression levels of the acetylated histone H3 lysine 27 (H3K27ac), accompanied by a decrease in histone H3 lysine 27 trimethylation (H3K27Me3) at *Nrf2* promoter in TRAMP-C1 cells [232].

#### 4.3.2. Cucurbitacin B

Cucurbitacin B (Figure 4) is a plant-derived triterpene, initially found in the cucurbitaceae plant species. Published research has indicated that this molecule acts as a potent HDAC inhibitor at sub-IC₅₀ and at IC₅₀ in the nanomolar range (IC₅₀ = 60 nM) for non-small cell lung cancer cells (NSCLC H1299 cells). Cucurbitacin B induced suppression of the activity and expression levels of epigenetically modifying marks. It also produced histone changes at the p16INK4A, p21CIP1/WAF1, and hTERT promoters in human NSCLC H1299 cells [233]. An in vivo experiment using a mouse model for lung cancer showed that cucurbitacin B at a concentration of 0.2 mg/kg b.w significantly inhibits the expression levels of different HDAC proteins (1–4), without visible signs of toxicity in animals.
4.2. Alkaloids

Alkaloids such as berberine, nicotinamide, isofistularin-3, psammaplin, and TSA (Table 2, Figure 3) exhibit promising anticancer effects via the control of epigenetic changes and various other mechanisms. The HDAC signaling pathways represent some of the main targets of these bioactive compounds. In this context, berberine (120 μM) exhibits remarkable anticancer effects via targeting epigenetic chromatin modification, which affects the enzyme implicated in histone acetylation and methylation in acute myeloid leukemia (AML) cell lines [224]. These events revealed the role of berberine as a master epigenetic regulator responsible for controlling downstream bioactivities, including cell cycle arrest, apoptosis, and the underlying mechanism of metabolic disorders and immune response.

Figure 3. Chemical structures of natural HDAC alkaloids in human cancers.

4.3.3. Ursolic Acid

Ursolic acid (3-beta-3-hydroxy-urs-12-ene-28-oic-acid) (Figure 4) is a triterpenic acid distributed in different plants and foods, such as ginseng (Panax Ginseng), rosemary (Rosmarinus officinalis), apple peel, pear, cranberry, and plum (Prunus domestica) [234,235]. It has been widely explored for its chemopreventive and chemotherapeutic effects on various cancers. Ursolic acid has been investigated for its action against different epigenetic regulators, including HDAC proteins. Research findings showed that this bioactive compound considerably downregulates the expression of several epigenetic modulatory factors, starting at a dose of 2.5 μM (non-toxic concentrations), including HDAC1, HDAC2, HDAC3, and HDAC8 (Class I), in addition to HDAC6 and HDAC7 (Class II) [232]. Ursolic acid also suppressed induction of HDAC1 and HDAC3 markers in leukocytes, mediated by LPS in mouse epidermal cells [232].
Figure 4. Chemical structures of HDAC natural terpenoids in human cancers.

Table 3. Natural terpenoids targeting HDAC in human cancers.

| Molecules (Origins) | Used Models          | Methods                                      | Key Findings                                                                                                                                                                                                 |
|---------------------|----------------------|----------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Corosolic acid      | TRAMP-C1 cells       | RT-PCR, DNA extraction, HDAC activity        | Increased the acetylation of histone H3 lysine 27 (H3K27ac). Reduced trimethylation of histone H3 lysine 27 (H3K27Me3) in the Nrf2 promoter region. Reduced the expression and activity of epigenetically modifying enzymes in TRAMP-C1 cells. |
|                     |                      | ChIP assay, Western blot analysis            |                                                                                                                                                                                                            |
|                     |                      |                                              | [232]                                                                                                                                                                                                       |
| Cucurbitacin B      | NSCLC cells          | RT-PCR, Western blot analysis, HDAC activity | Altered histone modifications.                                                                                                                                                                              |
| (L. graveolense Roxb.) |                      | Immunohistochemical staining                 |                                                                                                                                                                                                            |
|                     |                      |                                              | [233]                                                                                                                                                                                                       |
| Parthenolide (PTL)  | ZR-75-1 and 293T cells | RT-PCR, HDAC activity, Western blot analysis | Depleted HDAC1 protein, without affecting class I/II HDAC proteins. HDAC1 depletion and cell death were promoted by the mutant DNA-damage transducer ataxia telangiectasia.                                      |
| (Purchased)         |                      | ChIP assay                                   |                                                                                                                                                                                                            |
|                     |                      |                                              | [236]                                                                                                                                                                                                       |
Table 3. Cont.

| Molecules (Origins) | Used Models | Methods | Key Findings | Ref. |
|---------------------|-------------|---------|--------------|------|
| Parthenolide (PTL) (Purchased) | AML cells | Methylcellulose colony-forming Western blot analysis Flow cytometry | HDAC induced apoptosis was prevented in multiple human AML cells. Increased HDAC-induced lethality. PTL + HDACis caused apoptosis in MLL-ENL cells. PTL + HDACis triggered SAPK/JNK activation. | [237] |
| Parthenolide (PTL) (Not reported) | JB6 cells | Western blot analysis ChIP method RT-PCR siRNA transfection | HDAC activity Modulated gene expression. | [238] |
| Parthenolide (PTL) (Purchased) | MDA-MB231 cell line | Cell viability assessment ROS and GSH analysis Western blot analysis | HDACi-induced hyperacetylation of histones H3 and H4 and PTL-induced downregulation of DNMT1 expression PTL + HDACi boosted PTL’s cytotoxic impact. | [239] |
| Ursolic acid (Purchased) | JB6 P+ cells | qPCR Western blot analysis HDAC activity assay | Reduced the expression of HDAC1, 2, 3, and 8 (Class I) enzymes and the activity of HDAC6 and 7 (Class II). | [240] |
| Ursolic acid (Purchased) | Male Sprague-Dawley rats | mRNA expression measurement qPCR Development of PK/PD model | Inhibited the induction of epigenetic markers in leukocytes. | [232] |
| Z-Ligustilide (LIG) (Purchased) | HS578t, MDA-MB-231 and MDA-MB-453 cells | Western blot analysis Luciferase assay ChIP assay Immunoprecipitation | Increased Ace-H3 (lys9/14) enrichment in the ER promoter. Downregulated the HDAC activity. | [241] |

4.4. Fatty Acids

4.4.1. Butyrate

Butyrate is a short-chain fatty acid, mainly generated during the fermentation of carbohydrates by the intestinal microflora [242]. This molecule exerts an efficient epigenetic effect, acting as an HDAC inhibitor (Table 4). In this respect, Saldanha and coworkers [206] reported that butyrate induces important epigenetic modifications at relatively high, but physiologically achievable, concentrations (5 mM), as it affects the global DNA methylation and chromatin structure; thus, inhibiting HDAC1 expression in RKO, HCT-116, and HT-29 colorectal cancer cell lines. Moreover, butyrate decreased the reverse expression of HDAC1 in human esophageal 9706 cancer cells [223]. The combination of butyrate with quercetin showed the reverse effect, triggering remodeled DNA methylation and histone acetylation; thus, inhibiting HDAC activity [223]. This effect was mediated by NF-κB epigenetic signaling cascades. Generally, butyrate, through its epigenetic regulatory effects on HDACs, exhibits functions as a modulator of chromatin structure and may mediate cellular responses via up-regulatory genes responsible for cell cycle arrest, promoting therapeutic outcomes.
4.4.2. Butyric Acid and Eicosapentaenoic Acid

Butyric and eicosapentaenoic acids are fatty acids with several vegetable sources and exhibit important biological properties, including anticancer activity with different mechanisms, such as their effect on epigenetic targets (Table 4). Tiwari and Gupta [226] reported, in vivo, the antitumor activity of butyrate alone (17.62 mg) or combined with other compounds, including nicotinamide (NA) (5 mg) and calcium glucarate (CAG) (5 mg). The results showed that butyric acid exhibits a promising effect on 7,12-dimethylbenz[a]anthracene (DMBA)-induced tumor through increasing HDAC expression and activity, accompanied by upregulation of miR-203 promoter methylation at 4 or 16 weeks [226]. This effect was intensively promoted by co-administration of butyric acid with NA and CAG, targeting epigenetic or biogenetic modulations. On the other hand, treatment with eicosapentaenoic acid (100 µM) promoted the expression of the tumor suppressor gene by downregulating the expression levels of the HDAC1 enzyme, mediated by the activation of peroxisome proliferator-activated receptor (PPARγ) in hepatocarcinoma cells (HCC).

Table 4. Natural fatty acids targeting HDAC in human cancers.

| Molecules (Origins)     | Used Models                  | Methods                          | Key Findings                                                                                                                                   | Ref.  |
|-------------------------|------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-------|
| Butyrate (Purchased)    | Eca9706 cells                | MTT assay                        | Inhibited the development of human esophageal cancer cells. Reduced NF-Bp65, DNMT1, HDAC1, and Cyclin D1 reverse expression. Increased caspase-3 and p16INK4 expression. Butyrate + quercetin acted as HDAC inhibitors through epigenetic-NF-κB cascade signaling. | [223] |
| Butyrate (Purchased)    | CRL-2577, HT-29, and HCT-116 cells | HDAC activity assessment CpG methylation ChIP assay | Inhibited survivin, DNMT1, and HDAC1. Affected chromatin structure and global DNA methylation.                                               | [206] |
| Butyric acid (Purchased) | Female mice skin             | Bisulfite modification of DNA RT-PCR assay | Decreased miR-203 expression. Upregulated the methylation of DNMT, HDAC, and miR-203.                                                      | [226] |
| Eicosapentaenoic acid (EPA) (Purchased) | McRH-7777 cells | Flow cytometry qRT-PCR Immunoblot analysis ChIP method | Reduced HDAC1 and DNMT activity and expression. Promoted tumor suppressor gene expression. Activated PPAR by inhibiting HDAC1 expression in hepatocarcinoma cells. Re-expressed the tumor suppressor gene Hic-1 in response to EPA-bound PPAR. | [243] |

4.5. Isothiocyanate

4.5.1. Phenethyl Isothiocyanate (PEITC)

Phenethyl isothiocyanate (PEITC) (Figure 5, Table 5), is a secondary plant metabolite, naturally present as gluconasturtiin in numerous cruciferous vegetables, and has shown remarkable anticancer properties via multiple mechanisms, including as an epigenetic regulator. In one study, PEITC was used at multiple doses (0–20 µM). Long-term PEITC treatment (6 weeks; 2.5 µM) resulted in a 40% reduction in viability compared to cells exposed to the DMSO vehicle alone, but similar effects were not evident in a culture of 72 h, demonstrating that 2.5 µM PEITC is not highly cytotoxic in short-term cultures [244].

Several HDACs, including HDAC1, HDAC3, SAP18 (sin3-associated protein 18), and SAP30 (sin3-associated protein 30), showed preferential attachment to heterochromatin after exposure to PEITC, indicating that PEITC may prevent HDAC binding from opening.
areas of active euchromatin. On the other hand, short-term PEITC treatment had very minor impacts on the distribution of histone epigenetic regulators in SW620 cells, suggesting that long-term exposure is required to generate persistent and heritable alterations in tumor cell epigenetic profiles [244]. In human colon carcinoma cell line HT29, PEITC demonstrated a cytotoxic effect with an IC₅₀ of 11.88 µM [245]. Further in vivo investigation using PEITC indicated that a daily dose of 60 mg/kg p.o for 21 days could inhibit HDAC overexpression in rats [245].

4.5.2. Sulforaphane (SFN)

Sulforaphane (1-isothiocyanato-4-(methylsulfinyl)butane) (Figure 5) is an isothiocyanate mainly distributed in diverse cruciferous vegetables, such as broccoli, cabbage, brussel sprouts, and radish [246]. Treatment with SFN (15 µM and 20 µM) for six days decreased the growth of MCF10A cells, suggesting that these concentrations may be hazardous to normal breast cells. Breast cancer cells are preferentially inhibited at doses of

Figure 5. Chemical structures of different compounds associated with HDAC in human cancers.
10 µM or less. Sulforaphane therapy at a dose of 10 µM was shown to dramatically suppress HDAC activity in breast cancer cells [247]. Similar events were also noticed in A549 and H1299 lung cancer cells, where SFN significantly inhibited HDAC activity and upregulated the expression levels of acetylated histones H3 and H4 [248]. On the other hand, SFN increased the anti-oncogene proteins DUSP4 and CDK expression, which correlated with the downregulation of HDAC5 and HDAC11 genes in the hepatocarcinoma HepG2 cell line [249]. Listed in Table 5 are natural compounds that target HDAC in human cancers.

Table 5. Other natural molecules targeting HDAC in human cancers.

| Molecules (Origins) | Used Models | Methods | Key Finding | Ref. |
|---------------------|-------------|---------|-------------|------|
| **Isothiocyanate**  |             |         |             |      |
| Phenethyl isothiocyanate (PEITC) (Not reported) | HCT116, SW480, and SW620 cells | Cell viability, Western blot analysis, Quantitative RT-PCR | Induced stable changes in the expression profile of epigenetic erasers/writers. Induced hypomethylation of PcG target genes, which are generally hypermethylated in cancer. | [244] |
| Phenethyl isothiocyanate (PEITC) (Purchased) | HT29 (Colon cells) | Determination of HDAC1 levels | PEITC + LA reduced the amount of aberrant crypt foci, as well as DNMT1 and HDAC1 levels (in vivo). | [245] |
| **Sulforaphane (SFN)** (Not reported) | MCF-7 and MDA-MB-231 | RT-PCR, Western blot analysis, HDAC and HAT activity, Bisulfite sequencing analysis, ChIP method | Inhibited hTERT in both cells. Reduced the trimethyl-H3K9 and trimethyl-H3K27 in active chromatin indicators in a dose-dependent manner. | [189] |
| Sulforaphane (SFN) (Purchased) | HeLa cells | DNMT and HDAC activity assessment, Molecular docking study, Bisulfite Modification and MSP, RT-PCR | Inhibited the activity of HDAC. Lowered the HDAC1 expression. Reactivated RAR, CDH1, DAPK1, and GSTP1 genes or elevated their expression. | [207] |
| Sulforaphane (SFN) (Purchased) | A549 and H1299 (Lungs cells) | HDAC activity assay, qRT-PCR, Tumor xenografts | Inhibited the activity of HDAC in lung cancer cells. Increased histone (H4 and H3) acetylation. Suppressed the activity of HDAC in vivo. | [249] |
| Sulforaphane (SFN) (Purchased) | MCF-7 and MDA-MB-231 | HDACs activity assay | SFN + WA decreased HDAC expression. | [250] |
| Sulforaphane (SFN) (Purchased) | A549, HEK293, HT29 cells | Bisulfite genome sequencing, RT-PCR, Western blot analysis, ChIP method, HDAC and DNMT activity assessment | Reduced CpG methylation in the miR-9-3 promoter region. Increased H3K4me1 enrichment at the miR-9-3 promoter. Induced the expression of miR-9-3. Reduced the epigenetic modifying enzymes' expression and activity. | [251] |
Table 5. Cont.

| Molecules (Origins) | Used Models | Methods | Key Finding | Ref. |
|---------------------|-------------|---------|-------------|------|
| Sulforaphane (SFN) (Purchased) | Breast cancer cells | RT-PCR Western blot analysis HDACs activity Global histone H3 acetylation quantification RNA sequencing analysis | Increased gene transcription in tumor suppressor genes. Decreased the expression of tumor promoting genes. Decreased HDAC1 gene expression and enzymatic activity. Increased levels of histone acetylation. | [252] |
| Sulforaphane (SFN) (Purchased) | HCT116 and RKO (Colon cells) | RT-PCR Western blot analysis HDAC activity | Reduced the oncogenic hTERT mRNA, HDAC, miR-21, protein, and enzyme levels. | [253] |
| Sulforaphane (SFN) (Purchased) | MCF-7 and MDA-MB-231 | RT-PCR Western blot analysis HDAC activity | SFN + GEN suppressed HDAC and HMT. SFN + GEN inhibited the expression of hTERT. | [214] |
| Sulforaphane (SFN) (Not reported) | HepG2 and GAS cells | RNA-Seq analysis | Inhibited HDAC activity. Downregulated chromatin profile regulating enzymes. | [254] |
| Sulforaphane (SFN) (Purchased) | HepG2 cells | RNA extraction RNA-Seq analysis | Inhibited HDAC activity. Methylation of oncogenic TF binding site motifs affected its activity. | [249] |

**Quinones**

| Laccaic acid (LA) (Purchased) | HT29 cells | HDAC activity assay | LA + PEITC reduced HDAC1 expression levels (in vivo). | [255] |
| Naphthazarin (Naph) (Purchased) | MCF-7 cells | RT-PCR Western blot analysis ChIP method | Activated the p21 promoter by Naph + IR, by inhibiting the binding of multi-domain proteins. | [256] |
| Thymoquinone (Purchased) | JK cell line and MDA-MB-468 cells | Gene analysis RT-PCR analysis | Downregulated numerous major epigenetic factors. | [257] |

**Carotenoid**

| Astaxanthin (Purchased) | LNCaP cells | Cell viability test HDAC activity assay | Inhibited HDAC activity in vitro. | [258] |

**Stilbenes**

| Resveratrol (RSV) (Purchased) | MDA MB 231 and MCF7 | Bisulfite conversion RT-PCR Western blot analysis | Decreased HDAC1 protein levels. | |
| Resveratrol (RSV) (Purchased) | HeLa, SiHa, and Caski cervical cells | Promoter methylation analysis Transient silencing of *UHRF1* | Induced PAX1 reactivation via its effect on HDAC, which is mediated through the downregulation of *UHRF1*, which may affect both histone acetylation and DNA methylation. | [259] |
| Resveratrol (RSV) (Not reported) | B16F10 and Tumor-bearing mouse model | Western blot analysis Luciferase reporter assays Bisulfite sequencing PCR ChIP assay | HDAC1 was recruited to the focal adhesion kinase (FAK) promoter region. | [260] |
| Molecules (Origins) | Used Models          | Methods                                           | Key Finding                                                                 | Ref. |
|--------------------|----------------------|---------------------------------------------------|------------------------------------------------------------------------------|------|
| Resveratrol (RSV)  | MDA-MB-231 and MCF-7 cells | MTT assay, Clonogenic method, HDAC activity | Reduced HDAC activity. [261]                                                 |      |
| Curcumin (Cur)     | Hep3B cells          | Histone purification, Histone acetylation assay, Western blot analysis, RT-PCR | Inhibited histone acetylation in the presence or absence of TSA. Inhibited the activity of HAT both in vitro and in vivo. Induced histone hypoacetylation in vivo. [262] |      |
| Curcumin (Cur)     | Raji cells           | Immunocytochemistry analysis, Western blot analysis | Reduced HDAC1, HDAC3, and HDAC8 protein expression levels. Increased Ac-histone H4 protein expression. [263] |      |
| Curcumin (Cur)     | Raji cells           | MTT assay, Western blot analysis, RT-PCR          | Decreased the amounts of HDAC3, HDAC1, and p300. Reversed the protection degradation of p300 and HDAC1 by MG-132. [264] |      |
| Curcumin (Cur)     | Hela cells           | HDAC activity assessment                         | Inhibited the HDAC activity (IC_{50} = 115 µM). [265]                       |      |
| Curcumin (Cur)     | DAOY, D283 Med, and D341 Med (medulloblastoma) | HDAC activity in vivo, medulloblastoma xenografts | Reduced the HDAC4 activity and expression. Increased tubulin acetylation. [266] |      |
| Curcumin (Cur)     | LNCaP cells          | Western blot analysis, DNA extraction and bisulfite genomic sequencing, PCR array, RNA isolation and RT-PCR, ChIP assay, Histone H3 methylated lys27 ELISA, HDAC activity assay | Altered HDAC expression. Increased the expression of HDAC1, 4, 5, and 8, but decreased the HDAC3. Decreased HDAC activity. Decreased H3K27me3 enrichment at the Neurog1 promoter region and at the global level. [267] |      |
| Curcumin (Cur)     | MCF7 and MDA MB 231  | Bisulfite conversion and MSP, RT-PCR, Western blot analysis | Decreased protein levels of HDAC1.                                           |      |
| Curcumin (Cur)     | HeLa, SiHa, and Caski cells | MTT assay, Quantitative expression of PAX1, UHRF1, and p21, PAX1 promoter methylation analysis, Transient silencing of UHRF1 | Induced reactivation of PAX1, due to its effect on HDAC. [259] |      |
### Table 5. Cont.

| Molecules (Origins) | Used Models | Methods | Key Finding | Ref. |
|---------------------|-------------|---------|-------------|------|
| Calebin-A (Not reported) | MPNST cells | Cell proliferation Western blot analysis Flow cytometry ChIP assay | Reduced the expression of acetyl H3 proteins. | [268] |
| Pterostilbene (PTS) (Purchased) | MDA-MB-157, HCC1806, and MCF10A | RT-PCR Western blot analysis SIRT activity assay DNMT activity | RSV + PTS downregulated the SIRT1 (a type III HDAC). | [269] |
| **Steroids** | | | | |
| Guggulsterone (Purchased) | Breast cancer cells | Bisulfite conversion and MSP RT-PCR Western blot analysis | Decreased protein levels of HDAC1. | |
| Withaferin A (WA) (Purchased) | Breast cancer cells | Bisulfite conversion and MSP RT-PCR Western blot analysis | Decreased HDAC1 and MeCP2 protein levels. | |
| Withaferin A (WA) (Purchased) | Breast cancer cells | qRT-PCR Western blot analysis HDAC activity | WA + SFN decreased the HDAC activity and expression. | [250] |
| **Phenolic acids** | | | | |
| Chlorogenic acid (Purchased) | Breast cancer cells | In vitro HDAC inhibition | Inhibited the HDAC activity ($IC_{50} = 375 \mu M$). | [265] |
| Caffeic acid (Purchased) | Breast cancer cells | In vitro HDAC inhibition | Moderately inhibited the HDAC activity ($IC_{50} = 2.54 \text{mM}$). | [265] |
| **Secoiridoids** | | | | |
| Oleacein (Olea europaea L.) | U266, NCI-H929, RPMI-8226, MM1s, and JJN3 cells | Western blot analysis qRT-PCR HDAC activity | Accumulated α-tubulin and acetylated histones. Downregulated multiple Class I/II HDACs. Inhibited HDACs with downregulation of Sp1. | [270] |
| **Tannins** | | | | |
| Ellagic acid (EA) (Purchased) | hASCs cells | qPCR Western blot analysis HDAC activity Immunocytochemistry of H3R17me2 and HDAC9 | Inhibited HDAC 9 downregulation. Reduced the histone acetylation levels. | [271] |
| **Tanshinone** | | | | |
| Tanshinone IIA (Purchased) | HepG2-C8, JB6 P+, JB6-shNrf2 cells | Luciferase reporter activity assay RNA extraction and qRT-PCR Western blot analysis HDAC activity Bisulfite sequencing ChIP method | Inhibited HDAC activity. | [272] |
Table 5. Cont.

| Molecules (Origins)       | Used Models       | Methods                                | Key Finding                                                                 | Ref.     |
|--------------------------|-------------------|----------------------------------------|----------------------------------------------------------------------------|----------|
| Arsenic trioxide (AS$_2$O$_3$) (Purchased) | HeLa or HEK293T cells | Luciferase reporter assay, RT-PCR, ChIP method, Flow cytometry | Reduced global histone through direct binding. Increased HDAC4 expression. Inhibited the hMOF activity. | [273]    |
| Calcium glucarate (CAG) (Purchased) | Female mice cells | RT-PCR, Bisulfite sequencing assay, Western blot analysis | Downregulated the levels of miR-203. Upregulated DNMT, HDAC, and promoter methylation of miR-203. | [226]    |
| Proanthocyanidins (GSPs) | Breast cancer cells | Western blot analysis, HDAC activity | Reduced HDAC activity.                                                   | [261]    |
| Curcumol (Not reported)  | CSLCs cells       | qRT-PCR, Western blot analysis, Global DNA methylation, HDAC activity, Xenograft tumorigenicity assay, Immunohistochemistry | Blocked DNMT/HDAC activity and CSLC self-renewal in vivo and in vitro. Affected CLSCs by HDAC regulation. | [274]    |
| Selenium (Se) (Not reported) | LNCaP cells | HDAC activity                          | Reduced HDAC activity. No alteration of mRNA and protein levels of HDACs. Reduced methylated histone H3 on lysine 9 (H3-K9) levels. Increased acetylated H3-K9 levels. | [275]    |

4.6. Quinones

4.6.1. Naphthazarin

Naphthazarin (5,8-dihydroxy-1,4-naphthoquinone) (Figure 5) is a naturally occurring bioactive compound that shows various biological effects, such as antioxidant, antiparasitic, antifungal, and anticancer activities [247,248]. The viability of MCF-7 cells treated with naphthazarin was reduced in a dose-dependent manner (0–5 µM). Real-time PCR findings revealed that naphthazarin reduced HDAC1 mRNA expression in a dose-dependent manner [256]. This molecule inhibited the expression of HDAC1, resulting in increased expression levels of p21 cell cycle inhibitor, accompanied by a reduction in the expression of the chromatin effector proteins UHRF1 in MCF-7 [256].

4.6.2. Thymoquinone

Thymoquinone (TQ) (Figure 5) is the main bioactive compound of the black seed, Nigella sativa L. It possesses various health benefits and biological activities, including anticancer, anti-inflammatory, antiviral, antioxidant, antiparasitic, antimicrobial, immunomodulatory, and anticoagulant properties [250,251]. Moreover, TQ at doses of 5, 10, and 20 µM decreased cell proliferation and the expression of UHRF1, DNMT1, G9a, and HDAC1 genes in Jurkat cells and MDA-MB-468 cells [257].

4.7. Stilbenes

4.7.1. Resveratrol

Resveratrol (3,5,4′-trihydroxystilbene) (Figure 5) is a bioactive compound, first extracted from the roots of white hellebore (Veratrum grandiflorum Loes.) by Saiko et al. [276]. This bioactive compound is found in more than 50 different plant species, including grapes,
apples, blueberries, plums, and peanut. It has been extensively explored for its health benefits against diverse pathologies, including cancer [277]. The cytotoxic evaluation of resveratrol against HeLa, SiHa, and Caski cells revealed that the IC$_{50}$ values were 17, 22, and 118 µM, respectively [259]. For Caski cells, treatment with resveratrol for four days increased $p21$ expression by 1.7-, 2.1-, and 28-fold, respectively, compared to control cells (HDAC inhibition is characterized by a rise in $p21$, which is controlled by UHRF1) [259].

The translocation of B16F10 tumor cells to the lungs was dramatically reduced after 20 days of intraperitoneal (50 mg/kg) resveratrol therapy in 7-week-old female mice. Resveratrol showed no cytotoxicity against B16F10 cells at a dose of 60 µM, and it was speculated that resveratrol is involved in its anti-migration function, since HDAC1 and ACAT1 are resveratrol targets [260]. Similarly, resveratrol treatments, even at low doses (10 µM), reduced the cell viability of MCF-7 and MDA-MB-231 cell lines in a dose-dependent manner. Using increasing amounts of resveratrol (0–100 µM), researchers found that it suppresses HDAC activity in both cell lines in a dose-dependent manner [278].

4.7.2. Curcumin

Curcumin (Figure 5) has been reported to be a potent epigenetic regulator that has multiple effects on HDAC expression and activity. Curcumin downregulated the expression levels of HDAC1, HDAC3, and HDAC8 proteins and histone acetyltransferase p300, increasing the Ac-histone H4 protein expression in Raji cells. Curcumin was used at different concentrations (6.25, 12.5, 25, 50, and 100 µmol/L). Compared to curcumin-treated cells (25 µmol/L for 24 h), the expression of HDAC1, HDAC3, and HDAC8 was considerably higher in Raji cells. When cells were treated with 25 µmol/L curcumin for 24 h, more than two-thirds of them could not multiply. The IC$_{50}$ for 24 h was 25 µmol/L [263]. Curcumin was found to inhibit histone acetyltransferase (HAT) activity in LNCaP cells at a concentration of 5 µM, and it has also been suggested to be a possible DNMT and HDAC inhibitor [267].

4.7.3. Calebin-A

Calebin-A (Figure 5) is a curcuminoid compound obtained from *Curcuma longa* roots. This molecule possesses various biological properties [279]. It inhibited the proliferation of the malignant peripheral nerve sheath tumor (MPNST (STS26T, ST8814, T265, and S462TY)). At concentrations of 12.5–25 µM, Calebin-A reduced the viability of MPNST cell lines. With a 25 µM dose of Calebin-A applied for 24 h; all MPNST cell lines had survival rates below 50%. On the other hand, HDAC activity in MPNST cells did not decrease significantly after treatment [268].

4.7.4. Pterostilbene

Pterostilbene (3,5-dimethoxy-4-hydroxystilbene) (Figure 5) is a naturally occurring bioactive compound found in grapes and numerous berries, especially blueberries. Chemically, pterostilbene is a phytoalexin dimethyl ether compound derived from resveratrol [280]. Combinatorial treatment of pterostilbene with resveratrol (5 µM) modulated gene expression in HCC1806 and MDA-MB-157 breast cancer cells through epigenetic processes, including modification of HDACs [269]. It induced a downregulation of SIRT1, a type III HDAC, which is involved in modifying histones and some non-histone proteins via deacetylation, and subsequently modulates cell proliferation, apoptosis, stress response, metabolism, cellular senescence, and tumorigenesis [269,281].

4.8. Steroids

4.8.1. Guggulsterone

Guggulsterone [4, 17(20)-pregnadiene-3, 16-dione] (Figure 5) is a phytosteroid compound isolated from the gum resin of *Commiphora wightii*. This compound has been shown to prevent and treat numerous types of cancers. In a study by Mirza et al., the IC$_{50}$ of guggulsterone for MCF 7 cells was 20 µM and for MDA MB 231 cells 15 µM, and at low
concentrations, guggulsterone induced a remarkable effect on the modulation of key epigenetic regulators, such as HDACs responsible for the activation of tumor suppressor genes. Moreover, it has been reported that this bioactive compound can reverse the epigenetic modifications resulting from DNA hypermethylation, via suppressing HDAC1 expression in both human breast cancer MCF7 and MDA-MB-231 cell lines.

4.8.2. Withaferin A (WFA)

Withaferin A (Figure 5) is a steroidal lactone extracted from the Withania somnifera, known for its antitumor properties, and targeting different hallmarks of cancer, including cell proliferation, migration, invasion, and angiogenesis, as well as the epigenetic process. WFA demonstrated chemopreventive effects against breast cancer, reversing the epigenetic changes via downregulation of HDAC1 protein levels in MCF7 and MDA-MB-231 cell lines. The IC$_{50}$ values for MCF 7 and MDA MB 231 cells were 8 and 10 µM, respectively. Downregulation was also observed in HDAC1 expression in MDA MB 231 cells. In another study, WFA alone or combined with SFN (at 1 and 5 µM, respectively) exhibited remarkable downregulation of HDAC1 expression at both mRNA and protein levels in the MCF7 and MDA-MB-231 cells, with a significant effect using combination therapy [250]. WFA with SFN also reduced HMT activities; however, they increased HAT activities, especially against MDA-MB-231 cells [250].

4.9. Phenolic Acids, Secoiridoids, Tannins, and Tanshinones

4.9.1. Phenolic Acids: Caffeic Acid Chlorogenic Acid

Caffeic acid and its derivative chlorogenic acid (Figure 5) are phenolic acids mainly found in numerous plants and have shown promising health benefits against several diseases. These two compounds are effective epigenetic agents, inhibiting HDAC activity. Using an in vitro HDAC assay, Bora-Tatar and co-workers [265] showed that chlorogenic acid exhibits potent inhibition of HDAC activity (IC$_{50}$ = 375 µM). In contrast, moderate inhibition was observed by caffeic acid (IC$_{50}$ = 2.54 mM).

4.9.2. Secoiridoids: Oleacein

Oleacein (Figure 5) is the most abundant phenolic compound of Olea europaea L. (olive), belonging to the secoiridoid class. This compound has shown to be an efficient epigenetic modulator on multiple myeloma cell lines (NCI-H929, RPMI-8226, U266, MM1s, and JJN3). In fact, oleacein was shown to reduce cell viability in a dose-dependent manner, 48 h after treatment, with IC$_{50}$s ranging from 5.0 to 20.0 µM. On the other hand, this molecule did not affect the vitality of PBMCs from healthy donors. Unlike the positive controls, TSA and SAHA, incubation with oleacein had no effect on the HDAC activity retrieved from nuclear extracts. These data imply that oleacein does not affect MM cell acetyloma through enzymatic HDAC suppression [270].

4.9.3. Secoiridoids: Ellagic Acid

Ellagic acid (EA) (Figure 5) is a ubiquitous phenolic compound extracted from various fruits and vegetables, and which is well-known for its bioactivity against different cancer cells. This compound has demonstrated effective epigenetic HDAC modification. A significant increase in the expression of the HDACs gene was observed in human adipogenic stem cells treated with EA (twenty-fold higher than the control). Furthermore, 10 µM EA inhibited HDAC9 downregulation after four days of cell treatment. This phenolic compound also reduced adipocyte development and differentiation by inducing histone arginine methylation, and thereby increased acetylated histone through epigenetic changes, mediated by coactivator-associated arginine methyltransferase 1 (CARM1) inhibition. The findings indicated that CARM1 inhibition induces suppression of H3R17 methylation, resulting in decreased H3K9 acetylation and HDAC9 dissociation [271].
4.9.4. Tanshinones: Tanshinone IIA

Tanshinone IIA (Figure 5) is a natural bioactive compound identified in the rhizome of *Salvia miltiorrhiza* Bunge. Wang et al. [272] investigated the role of tanshinone IIA in epigenetic pathways, illustrating its effect on HDAC modification. These researchers showed that this bioactive compound inhibited the enzymatic activity of HDACs by 50% in the tanshinone treatment concentration range of 5.0 to 10.0 µM. Tanshinone IIA also downregulated, in a concentration-dependent manner, HDAC1, HDAC3, and HDAC8 protein levels, by decreasing mRNA expression [272].

4.10. Other Molecules Targeting HDAC in Human Cancers

4.10.1. Arsenic Trioxide

Arsenic trioxide (As$_2$O$_3$), a naturally occurring inorganic compound and environmental pollutant, is considered a potent human carcinogen [273,282]. This compound has demonstrated an effective anticancer activity, acting on epigenetic regulators (Table 5); it increased HDAC4 expression in human HeLa and HEK293T cell lines [273]. Treatments conducted for 24–72 h in the concentration range of 0.2–0.8 µM showed that As$_2$O$_3$ induced histone H4K16 acetylation in a dose-dependent manner. Arsenic trioxide downregulated the global histone H4 acetylation at lysine 16 (H4K16ac) via direct binding to histone acetyltransferase human male absent on first (hMOF) in HeLa and HEK293T cell lines. Additionally, HAT in vitro assay showed that arsenic trioxide directly inhibits hMOF activity [273].

4.10.2. Curcumol

Curcumol (Figure 5) is a natural sesquiterpenoid isolated from numerous plants of the Zingiberaceae family and has demonstrated diverse biological properties, such as being anti-inflammatory, anti-proliferative, antioxidant, and antimicrobial [283]. Several research investigations have proven the potent anticancer activity of curcumol; targeting several checkpoints, including HDAC epigenetic mechanism. Curcumol has been shown to suppress choriocarcinoma cancer stem-like cell self-renewal (CSLCs) through HDAC activity (in vitro and in vivo). JEG cells treated with curcumol (75 µg/mL) for sphere formation showed 50% growth inhibition [274]. HDAC enzyme inhibition was assessed using a colorimetric kit assay after seven days of curcumol treatment.

4.10.3. Selenium

Research findings demonstrated that selenium is a potential chemopreventive agent against prostate cancer. In this line, Xiang et al. [275] studied the effect of a single dose of selenite (1.5 µM) for 7 days on the human prostate cancer cell line LNCaP. They reported that selenite could prevent prostate cancer through an epigenetic mechanism by maintaining the expression of GSTP1 promoter, inducing the inhibition of DNA and histone methylation, and enhancing histone acetylation. In addition, selenite treatment altered HDAC expression and significantly affected its activity. It decreased the expression levels of methylated histone H3 on lysine 9 (H3-K9) and increased the expression of acetylated H3-K9 [275].

5. Conclusions

In summary, this work has highlighted the close relationship between the enzymes that regulate chromatin architecture and tumor transformation. Indeed, HDACs are responsible, along with other epigenetic modifiers, for maintaining cellular memory during mitotic division. Disturbances of HDAC activities correlate with tumor transformation in several cancers. Through our bibliographic research, we have shown that natural bioactive substances can modify the enzymatic activity of HDAC, and, therefore, its regulation. These remarkable results demonstrate the possible pharmacological effects of these substances and their applications in cancer chemotherapy. However, further testing needs to be performed on these bioactive compounds, to first confirm their safety by investigating their toxicity, and with other in vivo tests, to assess their pharmacokinetics.
validation of these approaches could pave the way for the clinical use of some of these molecules against cancer.

**Author Contributions:** Conceptualization, A.B., P.W. and M.S.M. methodology, A.B. and N.E.O.; validation, N.E.O., A.B., H.M. and P.W.; formal analysis, N.E.H., T.A., T.B., M.A.S. and M.S.M.; investigation, N.E.H., T.A. and A.B.; resources, N.E.O.; data curation, N.E.O. and N.E.H.; writing—original draft preparation, A.B., N.E.H., T.A., M.A.S. and I.B.; writing—review and editing, A.B., J.M.L., P.W., P.B. and M.S.M.; visualization, A.B., H.M. and T.B.; supervision, A.B.; project administration, A.B. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was not supported by any funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** No applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Mansoori, B.; Mohammadi, A.; Davudian, S.; Shirjang, S.; Baradaran, B. The Different Mechanisms of Cancer Drug Resistance: A Brief Review. *Adv. Pharm. Bull.* 2017, 7, 339–348. [CrossRef] [PubMed]

2. Bouyahya, A.; El Meniyi, N.; Oumeslakht, L.; El Allam, A.; Balahbib, A.; Rauf, A.; Muhammad, N.; Kuznetsova, E.; Derkho, M.; Thiruvengadam, M.; et al. Preclinical and Clinical Antioxidant Effects of Natural Compounds against Oxidative Stress-Induced Epigenetic Instability in Tumor Cells. *Antioxidants* 2021, 10, 1553. [CrossRef] [PubMed]

3. Mann, B.S.; Johnson, J.R.; Justice, R.; Pazdur, R. FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma. *Oncologist* 2007, 12, 1247–1252. [CrossRef] [PubMed]

4. Lee, J.; Huang, S. Cancer Epigenetics: Mechanisms and Crosstalk of a HDAC Inhibitor, Vorinostat. *Chemotherapy* 2013, 2, 14934. [CrossRef] [PubMed]

5. Richon, V.M. Cancer Biology: Mechanism of Antitumour Action of Vorinostat (Suberoylanilide Hydroxamic Acid), a Novel Histone Deacetylase Inhibitor. *Br. J. Cancer* 2006, 95, S2–S6. [CrossRef]

6. Coiffier, B.; Coiffier, F.; Prince, H.M.; Foss, F.; Sokol, L.; Greenwood, M.; Caballero, D.; Borchmann, P.; Morschhauser, F.; Emilie, M.; et al. Results from a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma after Prior Systemic Therapy. *J. Clin. Oncol.* 2012, 30, 631–636. [CrossRef]

7. Patra, S.; Praharaj, P.P.; Klionsky, D.J.; Bhutia, S.K. Vorinostat in Autophagic Cell Death: A Critical Insight into Autophagy-Mediated, -Associated and -Dependent Cell Death for Cancer Prevention. *Drug Discov. Today* 2022, 27, 269–279. [CrossRef]

8. Lee, H.-Z.; Kwitkowski, V.E.; Del Valle, P.L.; Ricci, M.S.; Saber, H.; Habtemariam, A.; Bullock, J.; Bloomquist, E.; Li Shen, Y.; Chen, X.-H.; et al. FDA Approval: Belinostat for Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. *Clin. Cancer Res.* 2015, 21, 2666–2670. [CrossRef]

9. Oki, Y.; Buglio, D.; Fanale, M.; Fard, L.; Copeland, A.; Romagueria, J.; Kwak, L.W.; Pro, B.; de Castro Faria, S.; Neelapu, S.; et al. Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma. *Clin. Cancer Res.* 2013, 19, 6882–6890. [CrossRef]

10. Peng, X.; Sun, Z.; Kuang, P.; Chen, J. Recent Progress on HDAC Inhibitors with Dual Targeting Capabilities for Cancer Treatment. *Eur. J. Med. Chem.* 2020, 208, 112831. [CrossRef]

11. Bouyahya, A.; El Omari, N.; Hakur, M.; El Hachafi, N.; Charfi, S.; Balahbib, A.; Guoouguoou, F.-E.; Rebezov, M.; Maksimiuk, N.; Shariati, M.A.; et al. Sources, Health Benefits, and Biological Properties of Zeaxanthin. *Antioxidants* 2021, 7, 339–348. [CrossRef] [PubMed]

12. El Omari, N.; El Meniyi, N.; Hachafi, N.; Rachidi, F.; El Meniyi, N.; Salhi, N.; Mrabti, H.; Barak, S.; Zengin, G.; Bouyahya, A. Health Beneficial and Pharmacological Properties of P-Cymene. *Food Chem. Toxicol.* 2021, 153, 112259. [CrossRef] [PubMed]

13. El Hachafi, N.; Lakhder, F.; Khouchar, A.; Barkim, S.; El Omari, N.; Balahbib, A.; Shariati, M.A.; Zengin, G.; Fikri-Benbrahim, K.; Orlando, G.; et al. Health Benefits and Pharmacological Properties of Hinokitiol. *Processes* 2021, 9, 1680. [CrossRef]

14. El Omari, N.; El Meniyi, N.; Zengin, G.; Goh, B.H.; Gallo, M.; Montesano, D.; Naviglio, D.; Bouyahya, A. Anticancer and Anti-Inflammatory Effects of Tomentosin: Cellular and Molecular Mechanisms. *Nutrients* 2021, 13, 3714. [CrossRef]

15. El Omari, N.; Bakrim, S.; Balahbib, A.; Lorenzo, J.M.; Rebezov, M.; Shariati, M.A.; Aboulaghras, S.; Balahbib, A.; Khayrullin, M.; Bouyahya, A. Natural Bioactive Compounds Targeting Epigenetic Pathways in Cancer: A Review on Alkaloids, Terpenoids, Quinones, and Isothiocyanates. *Molecules* 2021, 26, 6882–6890. [CrossRef] [PubMed]

16. El Omari, N.; Balahbib, A.; Intara, H.; Guoouguoou, F.-E.; Balahbib, A.; Zengin, G.; Bouyahya, A. Anticancer Mechanisms of Phytochemical Compounds: Focusing on Epigenetic Targets. *Environ. Sci. Pollut. Res.* 2021, 28, 47869–47903. [CrossRef] [PubMed]

17. Baylin, S.B.; Jones, P.A. A Decade of Exploring the Cancer Epigenome—Biological and Translational Implications. *Nat. Rev. Cancer* 2011, 11, 726–734. [CrossRef] [PubMed]
18. Sandoval, J.; Esteller, M. Cancer Epigenomics: Beyond Genomics. Curr. Opin. Genet. Dev. 2012, 22, 50–55. [CrossRef]
19. Jones, P.A.; Baylin, S.B. The Epigenomics of Cancer. Cell 2007, 128, 683–692. [CrossRef]
20. Kanwal, R.; Gupta, S. Epigenetics and Cancer. J. Appl. Physiol. 2010, 109, 596–605. [CrossRef]
21. You, J.S.; Jones, P.A. Cancer Genetics and Epigenetics: Two Sides of the Same Coin? Cancer Cell 2012, 22, 9–20. [CrossRef] [PubMed]
22. Pfister, S.X.; Ashworth, A. Marked for Death: Targeting Epigenetic Changes in Cancer. Nat. Rev. Drug Discov. 2017, 16, 241–263. [CrossRef] [PubMed]
23. Holliday, R. DNA Methylation and Epigenetic Inheritance. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1990, 326, 329–338. [CrossRef]
24. Kristensen, L.S.; Nielsen, H.M.; Hansen, L.L. Epigenetics and Cancer Treatment. Eur. J. Pharmacol. 2009, 625, 131–142. [CrossRef] [PubMed]
25. Karimzadeh, M.R.; Pourdavoud, P.; Ehtesham, N.; Qadbeigi, M.; Asl, M.M.; Alani, B.; Mosallaei, M.; Pakzad, B. Regulation of DNA Methylation Machinery by Epi-MiRNAs in Human Cancer: Emerging New Targets in Cancer Therapy. Cancer Gene Ther. 2021, 28, 157–174. [CrossRef]
26. Ross, J.P.; Rand, K.N.; Molloy, P.L. Hypomethylation of Repeated DNA Sequences in Cancer. Epigenomics 2010, 2, 245–269. [CrossRef]
27. Eden, A.; Gaudet, F.; Waghmare, P.A.; Jaenisch, R. Chromosomal Instability and Tumors Promoted by DNA Hypomethylation. Science 2003, 300, 455. [CrossRef]
28. Esteller, M.; Corn, P.G.; Baylin, S.B.; Herman, J.G. A Gene Hypermethylation Profile of Human Cancer. Cancer Res. 2001, 61, 3225–3229.
29. He, J.; Zhou, M.; Li, X.; Gu, S.; Cao, Y.; Xing, T.; Chen, W.; Chu, C.; Gu, F.; Zhou, J. SLC34A2 Simultaneously Promotes Papillary Thyroid Carcinoma Growth and Invasion through Distinct Mechanisms. Oncogene 2020, 39, 2658–2675. [CrossRef]
30. Sastry, N.G.; Wan, X.; Huang, T.; Alvarez, A.A.; Pangeni, R.P.; Song, X.; James, C.D.; Horbinski, C.M.; Brennan, C.W.; Nakano, I. LY6K Promotes Glioblastoma Tumorigenicity via CAV1–Mediated ERK1/2 Signaling Enhancement. Neuro-Oncol. 2020, 22, 1315–1326. [CrossRef]
31. Xiao, C.; Wu, G.; Zhou, Z.; Zhang, X.; Wang, Y.; Song, G.; Ding, E.; Sun, X.; Zhong, L.; Li, S. RBBP6, a RING Finger-Domain E3 Ubiquitin Ligase, Induces Epithelial–Mesenchymal Transition and Promotes Metastasis of Colorectal Cancer. Cell Death Dis. 2019, 10, 833. [CrossRef] [PubMed]
32. Eads, C.A.; Lord, R.V.; Kurumoober, S.K.; Wickramasinghe, K.; Skinner, M.L.; Long, T.I.; Peters, J.H.; DeMeester, T.R.; Danenberg, K.D.; Danenberg, P.V. Epigenetic Inactivation of Tumor Suppressor Genes in Serum of Patients with Cutaneous Melanoma. J. Investig. Dermatol. 2001, 116, 3163–3178. [CrossRef]
33. Issa, J.-P.; Ahuja, N.; Toyota, M.; Bronner, M.P.; Brentnall, T.A. Accelerated Age-Related CpG Island Methylation in Ulcerative Colitis. Cancer Res. 2001, 61, 3573–3577.
34. Greger, V.; Passarge, E.; Höpping, W.; Messmer, E.; Horsthemke, B. Epigenetic Changes May Contribute to the Formation and Spontaneous Regression of Retinoblastoma. Hum. Genet. 1989, 83, 155–158. [CrossRef]
35. Herman, J.G.; Latif, F.; Weng, Y.; Lerman, M.I.; Zbar, B.; Liu, S.; Samid, D.; Duan, D.S.; Gnarra, J.R.; Linehan, W.M. Silencing of the VHL Tumor-Suppressor Gene by DNA Methylation in Renal Carcinoma. Proc. Natl. Acad. Sci. USA 1994, 91, 9700–9704. [CrossRef]
36. Gonzalez-Zulueta, M.; Bender, C.M.; Yang, A.S.; Nguyen, T.; Beart, R.W.; Van Tornout, J.M.; Jones, P.A. Methylation of the 5’ CpG Island of the P16/CDKN2 Tumor Suppressor Gene in Normal and Transformed Human Tissues Correlates with Gene Silencing. Cancer Res. 1995, 55, 4531–4535.
37. Kane, M.F.; Loda, M.; Gaida, G.M.; Lipman, J.; Mishra, R.; Goldman, H.; Jessup, J.M.; Kolodner, R. Methylation of the HMLH1 Promoter Correlates with Lack of Expression of HMLH1 in Sporadic Colon Tumors and Mismatch Repair-Defective Human Tumor Cell Lines. Cancer Res. 1997, 57, 808–811.
38. Richter, A.M.; Woods, M.L.; Küster, M.M.; Walesch, S.K.; Braun, T.; Boettger, T.; Dammann, R.H. RASSF10 Is Frequently Epigenetically Inactivated in Kidney Cancer and Its Knockout Promotes Neoplasia in Cancer Prone Mice. Oncogene 2020, 39, 3114–3127. [CrossRef]
39. Yu, Z.; Feng, J.; Wang, W.; Deng, Z.; Zhang, Y.; Xiao, L.; Wang, Z.; Liu, C.; Liu, Q.; Chen, S. The EGFR-ZNF263 Signaling Axis Silences SIX3 in Glioblastoma Epigenetically. Oncogene 2020, 39, 3163–3178. [CrossRef]
40. Marini, A.; Mirmohammadsadegh, A.; Nambiar, S.; Gustrau, A.; Ruzicka, T.; Hengge, U.R. Epigenetic Inactivation of Tumor Suppressor Genes in Serum of Patients with Cutaneous Melanoma. J. Investig. Dermatol. 2006, 126, 422–431. [CrossRef]
41. Mirmohammadsadegh, A.; Marini, A.; Nambiar, S.; Hassan, M.; Tannapfel, A.; Ruzicka, T.; Hengge, U.R. Epigenetic Silencing of the PTEN Gene in Melanoma. Cancer Res. 2006, 66, 6546–6552. [CrossRef] [PubMed]
42. Majumdar, S.; Buckles, E.; Estrada, J.; Koochekpour, S. Aberrant DNA Methylation and Prostate Cancer. Curr. Genom. 2011, 12, 486–505. [CrossRef] [PubMed]
43. Bell, A.; Bell, D.; Weber, R.S.; El-Naggar, A.K. CpG Island Methylation Profiling in Human Salivary Gland Adenoid Cystic Carcinoma. Cancer 2011, 117, 2898–2909. [CrossRef]
44. He, S.; Wang, F.; Yang, L.; Guo, C.; Wan, R.; Ke, A.; Xu, L.; Hu, G.; Xu, X.; Shen, J. Expression of DNMT1 and DNMT3a Are Regulated by GLI1 in Human Pancreatic Cancer. PLoS ONE 2011, 6, e27684. [CrossRef] [PubMed]
45. Baylin, S.B.; Ohm, J.E. Epigenetic Gene Silencing in Cancer–a Mechanism for Early Oncogenic Pathway Addiction? Nat. Rev. Cancer 2006, 6, 107–116. [CrossRef]

46. Markl, I.D.; Cheng, J.; Liang, G.; Shibata, D.; Laird, P.W.; Jones, P.A. Global and Gene-Specific Epigenetic Patterns in Human Bladder Cancer Genomes Are Relatively Stable in Vivo and in Vitro over Time. Cancer Res. 2001, 61, 5875–5884.

47. Nacev, B.A.; Feng, L.; Bagert, J.D.; Lemiesz, A.E.; Gao, J.; Sosnowy, A.A.; Kundra, R.; Schultz, N.; Muir, T.W.; Allis, C.D. The Expanding Landscape of ‘Oncohistone’Mutations in Human Cancers. Nature 2019, 567, 473–478. [CrossRef]

48. Zhao, S.; Bellone, S.; Lopez, S.; Thakral, D.; Schwab, C.; English, D.P.; Black, J.; Cocco, E.; Choi, J.; Zammataro, L. Mutational Landscape of Uterine and Ovarian Carcinosarcomas Implicates Histone Genes in Epithelial–Mesenchymal Transition. Proc. Natl. Acad. Sci. USA 2016, 113, 12283–12284. [CrossRef]

49. Schwatzentruber, J.; Korshunov, A.; Liu, X.-Y.; Jones, D.T.; Pfaff, E.; Jacob, K.; Sturm, D.; Fontebasso, A.M.; Quang, D.-A.K.; Tönjes, M. Driver Mutations in Histone H3. 3 and Chromatin Remodelling Genes in Paediatric Glioblastoma. Nature 2012, 482, 226–231. [CrossRef]

50. Wu, G.; Broniscer, A.; McEachron, T.A.; Lu, C.; Paugh, B.S.; Beckstort, J.; Qu, C.; Ding, L.; Huether, R.; Parker, M.S. Juvenile Children’s Research Hospital–Washington University Pediatric Cancer Genome Project. Somatic Histone H3 Alterations in Pediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas. Nat. Genet. 2012, 44, 251–253.

51. Koelsche, C.; Schrimpf, D.; Tharun, L.; Roth, E.; Sturm, D.; Jones, D.T.; Renker, E.-K.; Sill, M.; Baude, A.; Sahm, F. Histone 3.3 Hotspot Mutations in Conventional Osteosarcomas: A Comprehensive Clinical and Molecular Characterization of Six H3F3A Mutated Cases. Clin. Sarcoma Res. 2017, 7, 9. [CrossRef] [PubMed]

52. Lutsik, P.; Baude, A.; Mancarella, D.; Öz, S.; Kühn, A.; Toth, R.; Hey, J.; Toprak, U.H.; Lim, J.; Nguyen, V.H. Globally Altered Epigenetic Landscape and Delayed Osteogenic Differentiation in H3. 3G34W-Mutant Giant Cell Tumor of Bone. Nat. Commun. 2020, 11, 5414. [CrossRef]

53. Mohammad, H.P.; Barbash, O.; Creasy, C.L. Targeting Epigenetic Modifications in Cancer Therapy: Erasing the Roadmap to Cancer. Nat. Med. 2019, 25, 403–418. [CrossRef] [PubMed]

54. Fraga, M.F.; Ballestar, E.; Villar-Garea, A.; Boix-Chornet, M.; Espada, J.; Schotta, G.; Bonaldi, T.; Haydon, C.; Ropero, S.; Petrie, K. Loss of Acetylation at Lys16 and Trimethylation at Lys20 of Histone H4 Is a Common Hallmark of Human Cancer. Nat. Genet. 2005, 37, 391–400. [CrossRef] [PubMed]

55. Seligson, D.B.; Horvath, S.; Shi, T.; Yu, H.; Tze, S.; Grunstein, M.; Kurdistani, S.K. Global Histone Modification Patterns Predict Risk of Prostate Cancer Recurrence. Nature 2015, 433, 1262–1266. [CrossRef]

56. Prachayasittikul, V.; Prathipati, P.; Pratiwi, R.; Phanus-Umporn, C.; Malik, A.A.; Schaduangrat, N.; Seenprachawong, K.; Wongchitrat, P.; Supokawej, A.; Prachayasittikul, V. Exploring the Epigenetic Drug Discovery Landscape. Expert Opin. Drug Discov. 2017, 12, 345–362. [CrossRef]

57. Kubicek, S.; Gilbert, J.C.; Fomiina-Yadlin, D.; Gitlin, A.D.; Yuan, Y.; Wagner, F.F.; Holson, E.B.; Luo, T.; Lewis, T.A.; Taylor, B. Chromatin-Targeting Small Molecules Cause Class-Specific Transcriptional Changes in Pancreatic Endocrine Cells. Proc. Natl. Acad. Sci. USA 2012, 109, 5364–5369. [CrossRef]

58. Barski, A.; Cuddapah, S.; Cui, K.; Roh, T.-Y.; Schones, D.E.; Wang, Z.; Wei, G.; Chepelev, I.; Zhao, K. High-Resolution Profiling of Histone Methylation in the Human Genome. Cell 2007, 129, 823–837. [CrossRef]

59. Bradford, C.A.; Khanim, F.L.; Hayden, R.; Bunce, C.M.; White, D.A.; Drayson, M.T.; Craddock, C.; Turner, B.M. Histone Deacetylases in Acute Myeloid Leukaemia Show a Distinctive Pattern of Expression That Changes Selectively in Response to Deacetylase Inhibitors. Leukemia 2005, 19, 1751–1759. [CrossRef]

60. Fang, D.; Gan, H.; Cheng, L.; Lee, J.-H.; Zhou, H.; Sarkaria, J.N.; Daniels, D.J.; Zhang, Z. H3. 3K27M Mutant Proteins Reprogram the Epigenome of Chondroblastomas. Science 2016, 352, 541–546. [CrossRef] [PubMed]

61. Larson, J.D.; Kasper, L.H.; Paugh, B.S.; Jin, H.; Liu, X.-Y.; Broniscer, A.; McEachron, T.A.; Qu, C.; Ding, L.; Huether, R.; Parker, M.S.; Jones, P.A. Global and Gene-Specific Epigenetic Patterns in Human Bladder Cancer Genomes Are Relatively Stable in Vivo and in Vitro over Time. Cancer Res. 2001, 61, 5875–5884.
68. Narita, T.; Weinert, B.T.; Choudhary, C. Functions and Mechanisms of Non-Histone Protein Acetylation. *Nat. Rev. Mol. Cell Biol.* 2019, 20, 156–174. [CrossRef]

69. Marmorstein, R. Structure of Histone Acetyltransferases. *J. Mol. Biol.* 2001, 311, 433–444. [CrossRef]

70. Calcagno, D.Q.; Wisnieski, F.; Mota, E.R.; Maia de Sousa, S.B.; Costa da Silva, J.M.; Leal, M.F.; Giqek, C.O.; Santos, L.C.; Rasmussen, L.T.; Assumpção, P.P. Role of Histone Acetylation in Gastric Cancer: Implications of Dietetic Compounds and Clinical Perspectives. *Epigenomics* 2019, 11, 349–362. [CrossRef]

71. Gruber, J.J.; Geller, B.; Lipchik, A.M.; Chen, J.; Salahudeen, A.A.; Ram, A.N.; Ford, J.M.; Kuo, C.J.; Snyder, M.P. HAT1 Coordinates Histone Production and Acetylation by H4 Promoter Binding. *Mol. Cell* 2019, 75, 711–724. [CrossRef]

72. Shanmugam, M.K.; Arfuso, F.; Arumugam, S.; Chinnathambi, A.; Bian, J.; Warner, S.; Wang, L.Z.; Kumar, A.P.; Ahn, K.S.; Sethi, G. Correction: Role of Novel Histone Modifications in Cell Signaling. *Oncotarget* 2018, 9, 19460. [CrossRef] [PubMed]

73. Pasqualucci, L.; Dominguez-Sola, D.; Chierenza, A.; Fabbrì, G.; Grun, A.; Trifonov, V.; Kasper, L.H.; Lerach, S.; Tang, H.; Ma, J. Inactivating Mutations of Acetyltransferases Genes in B-Cell Lymphoma. *Nature* 2011, 471, 189–195. [CrossRef] [PubMed]

74. Chen, S.; Yin, C.; Lao, T.; Liang, D.; He, D.; Wang, C.; Sang, N. AMPK-HDAC5 Pathway Facilitates Nuclear Accumulation of HIF-1α and Functional Activation of HIF-1 by Decacyetylating Hsp70 in the Cytosol. *Cell Cycle* 2015, 14, 2520–2536. [CrossRef] [PubMed]

75. Narita, T.; Weinert, B.T.; Choudhary, C. Functions and Mechanisms of Non-Histone Protein Acetylation. *Nat. Rev. Mol. Cell Biol.* 2019, 20, 156–174. [CrossRef]

76. Davis, P.K.; Brachmann, R.K. Chromatin Remodeling and Cancer. *Nat. Rev. Cancer* 2010, 10, 389–402. [CrossRef] [PubMed]

77. Choudhary, C.; Kumar, C.; Gnad, F.; Nielsen, M.L.; Rehman, M.; Walther, T.C.; Olsen, J.V.; Mann, M. Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions. *Science* 2009, 325, 834–840. [CrossRef] [PubMed]

78. Cohen, P. The Origins of Protein Phosphorylation. *Nat. Rev. Mol. Cell Biol.* 2002, 4, E127–E130. [CrossRef]

79. Kasinski, A.L.; Slack, F.J. MicroRNA Gene Hsa-Mir-9-1 in Human Breast Cancer. *J. Pathol. A J. Pathol. Soc. Great Br. Irel.* 2007, 211, 433–444. [CrossRef] [PubMed]

80. Seeler, J.-S.; Dejean, A. SUMO and the Robustness of Cancer. *Nat. Rev. Cancer* 2010, 10, 184–197. [CrossRef] [PubMed]

81. Cohen, P. The Origins of Protein Phosphorylation. *Nat. Rev. Mol. Cell Biol.* 2002, 4, E127–E130. [CrossRef] [PubMed]

82. Ryan, B.M.; Robles, A.A.; Harris, C.C. Genetic Variation in MicroRNA Networks: The Implications for Cancer Research. *Nat. Rev. Cancer* 2010, 10, 389–402. [CrossRef] [PubMed]

83. Kasinski, A.L.; Slack, F.J. MiRNA-34 Prevents Cancer Initiation and Progression in a Therapeutically Resistant K-Ras and P53-Induced Mouse Model of Lung Adenocarcinoma. *Cancer Res.* 2012, 72, 5567–5587. [CrossRef] [PubMed]

84. Esquela-Kerscher, A.; Slack, F.J. Oncomirs—MicroRNAs with a Role in Cancer. *Nat. Rev. Cancer* 2006, 6, 259–269. [CrossRef] [PubMed]

85. Rezaei, T.; Amini, M.; Hashemi, Z.S.; Mansoori, B.; Rezaei, S.; Karami, H.; Mosafer, J.; Mokhtarzadeh, A.; Baradaran, B. MicroRNA-181b Serves as a Dual-Role Regulator in the Development of Human Cancers. *Free. Radic. Biol. Med.* 2020, 152, 432–454. [CrossRef] [PubMed]

86. Chen, S.; Yin, C.; Lao, T.; Liang, D.; He, D.; Wang, C.; Sang, N. AMPK-HDAC5 Pathway Facilitates Nuclear Accumulation of HIF-1α and Functional Activation of HIF-1 by Decacyetylating Hsp70 in the Cytosol. *Cell Cycle* 2015, 14, 2520–2536. [CrossRef] [PubMed]

87. Friedman, J.M.; Liang, G.; Liu, C.-C.; Wolff, E.M.; Tsai, Y.C.; Ye, W.; Zhou, X.; Jones, P.A. The Putative Tumor Suppressor MiRNA-29 Family Reverts Aberrant Methylation in Lung Cancer by Targeting DNA Methyltransferases 3A and 3B. *Science* 2008, 322, 2623–2629. [CrossRef] [PubMed]

88. Calin, G.A.; Dumitru, C.D.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; Keating, M.; Rai, K. Frequent Deletions and Down-Regulation of Micro-RNA Genes MiR15 and MiR16 at 13q14 in Chronic Lymphocytic Leukemia. *Proc. Natl. Acad. Sci. USA* 2002, 99, 15524–15529. [CrossRef] [PubMed]

89. Varambally, S.; Cao, Q.; Mani, R.-S.; Shankar, S.; Wang, X.; Ateeq, B.; Laxman, B.; Cao, X.; Jing, X.; Ramnarayanan, K. Genomic Loss of Micro-RNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer. *Science* 2008, 322, 1695–1699. [CrossRef] [PubMed]

90. Bandres, E.; Agirre, X.; Bitarte, N.; Ramírez, N.; Zarate, R.; Roman-Gomez, J.; Prosper, F.; Garcia-Foncillas, J. Epigenetic Regulation of MicroRNA Expression in Colorectal Cancer. *Int. J. Cancer* 2009, 125, 2737–2743. [CrossRef]

91. Chen, P.; Zhao, X.; Ma, L. Downregulation of MicroRNA-100 Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma. *Mol. Cell. Biochem.* 2013, 383, 49–58. [CrossRef]

92. Calcagno, D.Q.; Wisnieski, F.; Mota, E.R.; Maia de Sousa, S.B.; Costa da Silva, J.M.; Leal, M.F.; Giqek, C.O.; Santos, L.C.; Rasmussen, L.T.; Assumpção, P.P. Role of Histone Acetylation in Gastric Cancer: Implications of Dietetic Compounds and Clinical Perspectives. *Epigenomics* 2019, 11, 349–362. [CrossRef]

93. Bandres, E.; Agirre, X.; Bitarte, N.; Ramírez, N.; Zarate, R.; Roman-Gomez, J.; Prosper, F.; Garcia-Foncillas, J. Epigenetic Regulation of MicroRNA Expression in Colorectal Cancer. *Int. J. Cancer* 2009, 125, 2737–2743. [CrossRef]

94. Lehmann, U.; Hasemeier, B.; Christen, M.; Müller, M.; Römermann, D.; Längner, F.; Kreipe, H. Epigenetic Inactivation of MicroRNA Gene Hsa-Mir-9-1 in Human Breast Cancer. *J. Pathol. A J. Pathol. Soc. Great Br. Irel.* 2008, 214, 17–24.

95. Rezaei, T.; Amini, M.; Hashemi, Z.S.; Mansoori, B.; Rezaei, S.; Karami, H.; Mosafer, J.; Mokhtarzadeh, A.; Baradaran, B. MicroRNA-181b Serves as a Dual-Role Regulator in the Development of Human Cancers. *Free. Radic. Biol. Med.* 2020, 152, 432–454. [CrossRef] [PubMed]

96. Chiba, S. Dysregulation of TET2 in Hematologic Malignancies. *Int. J. Hematol.* 2017, 105, 17–22. [CrossRef]
96. Inomata, M.; Tagawa, H.; Guo, Y.-M.; Kameoka, Y.; Takahashi, N.; Sawada, K. MicroRNA-17-92 down-Regulates Expression of Distinct Targets in Different B-Cell Lymphoma Subtypes. *Blood J. Am. Soc. Hematol.* 2009, 113, 396–402. [CrossRef]

97. Wang, H.; An, X.; Yu, H.; Zhang, S.; Tang, B.; Zhang, X.; Li, Z. MiR-29b/TET1/ZEB2 Signaling Axis Regulates Metastatic Properties and Epithelial-Mesenchymal Transition in Breast Cancer Cells. *Oncotarget* 2017, 8, 102119. [CrossRef]

98. Lin, H.-Y.; Chen, C.-S.; Lin, S.-P.; Weng, J.-R.; Chen, C.-S. Targeting Histone Deacetylase in Cancer Therapy. *Med. Res. Rev.* 2006, 26, 397–413. [CrossRef]

99. Delcze, G.P.; Khan, D.H.; Davie, J.R. Roles of Histone Deacetylases in Epigenetic Regulation: Emerging Paradigms from Studies with Inhibitors. *Clin. Epigenetics* 2012, 4, 5. [CrossRef]

100. Ropero, S.; Esteller, M. The Role of Histone Deacetylases (HDACs) in Human Cancer. *Mol. Oncol.* 2007, 1, 19–25. [CrossRef]

101. Mercurio, C.; Minucci, S.; Pelicci, P.G. Histone Deacetylases and Epigenetic Therapies of Hematological Malignancies. *Pharmacol. Res.* 2010, 62, 18–34. [CrossRef]

102. Halkidou, K.; Gaughan, L.; Cook, S.; Leung, H.Y.; Neal, D.E.; Robson, C.N. Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer. *Prostate* 2004, 59, 177–189. [CrossRef] [PubMed]

103. Wilson, A.J.; Byun, D.-S.; Popova, N.; Murray, L.B.; L’Italien, K.; Sowa, Y.; Arango, D.; Velchic, A.; Augustlicht, L.H.; Mariadason, J.M. Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and P21 Expression and Are Deregulated in Human Colon Cancer. *J. Biol. Chem.* 2006, 281, 13548–13558. [CrossRef] [PubMed]

104. Choi, J.-H.; Kwon, H.J.; Yoon, B.-I.; Kim, J.-H.; Han, S.U.; Joo, H.J.; Kim, D.-Y. Expression Profile of Histone Deacetylase 1 in Gastric Cancer Tissues. *J. Cancer Res.* 2001, 92, 1300–1304. [CrossRef] [PubMed]

105. Zhang, Z.; Yamashita, H.; Toyama, T.; Sugitara, H.; Ando, Y.; Mita, K.; Hamaguchi, M.; Hara, Y.; Kobayashi, S.; Iwase, H. Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast. *Breast Cancer Res. Treat.* 2005, 94, 11–16. [CrossRef]

106. Zhu, P.; Martin, E.; Mengwasser, J.; Schlag, P.; Janssen, K.-P.; Götlinger, M. Induction of HDAC2 Expression upon Loss of APC in Colorectal Tumorigenesis. *Cancer Cell* 2004, 5, 455–463. [CrossRef]

107. Huang, B.H.; Laban, M.; Leung, C.H.; Lee, L.; Lee, C.K.; Salto-Tellez, M.; Raju, G.C.; Hooi, S.C. Inhibition of Histone Deacetylase 2 Increases Apoptosis and P21 Cip1/WAF1 Expression, Independent of Histone Deacetylase 1. *Cell Death Differ.* 2005, 12, 395–404. [CrossRef]

108. Song, J.; Noh, J.H.; Lee, J.H.; Eun, J.W.; Ahn, Y.M.; Kim, S.Y.; Lee, S.H.; Park, W.S.; Yoo, N.J.; Lee, J.Y. Increased Expression of Histone Deacetylase 2 Is Found in Human Gastric Cancer. *Apmis* 2005, 113, 264–268. [CrossRef]

109. Zhang, Z.; Yamashita, H.; Toyama, T.; Sugitara, H.; Omoto, Y.; Ando, Y.; Mita, K.; Hamaguchi, M.; Hayashi, S.; Iwase, H. HDAC6 Expression Is Correlated with Better Survival in Breast Cancer. *Clin. Cancer Res.* 2004, 10, 6962–6968. [CrossRef]

110. Ropero, S.; Fraga, M.F.; Ballestar, E.; Hamelin, R.; Yamamoto, H.; Boix-Chornet, M.; Caballero, R.; Alaminos, M.; Setien, F.; Paz, M.F. A Truncating Mutation of HDAC2 in Human Cancers Confers Resistance to Histone Deacetylase Inhibition. *Nat. Genet.* 2006, 38, 566–569. [CrossRef]

111. Zimmermann, S.; Kiefer, F.; Prudenziani, M.; Spiller, C.; Hansen, J.; Floss, T.; Wurst, W.; Minucci, S.; Götlinger, M. Reduced Body Size and Decreased Intestinal Tumor Rates in HDAC2-Mutant Mice. *Cancer Res.* 2007, 67, 9047–9054. [CrossRef]

112. Bhaskara, S.; Chyla, B.J.; Amann, J.M.; Knutson, S.K.; Cortez, D.; Leung, H.Y.; Neal, D.E.; Robson, C.N. Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer. *Prostate* 2004, 59, 177–189. [CrossRef] [PubMed]

113. Blaskara, S.; Chyla, B.J.; Amann, J.M.; Knutson, S.K.; Cortez, D.; Sun, Z.-W.; Hiebert, S.W. Deletion of Histone Deacetylase 3 Reveals Critical Roles in S Phase Progression and DNA Damage Control. *Mot. Cell 2008, 30, 61–72. [CrossRef]

114. Glaser, K.B.; Li, J.; Staver, M.J.; Wei, R.-Q.; Albert, D.H.; Daviden, S.K. Role of Class I and Class II Histone Deacetylases in Carcinoma Cells Using SiRNA. *Biochem. Biophys. Res. Commun.* 2003, 310, 529–536. [CrossRef] [PubMed]

115. Inoue, S.; Mai, A.; Dyer, M.J.; Cohen, G.M. Inhibition of Histone Deacetylase Class I but Not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis. *Cancer Res.* 2006, 66, 6785–6792. [CrossRef] [PubMed]

116. Weichert, W.; Rößke, A.; Niesporek, S.; Noske, A.; Buckendahl, A.-C.; Dietel, M.; Gekeler, V.; Boehm, M.; Beckers, T.; Denkert, C. Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylase in Vitro and in Vivo. *Clin. Cancer Res.* 2008, 14, 1669–1677. [CrossRef] [PubMed]

117. Wilson, A.J.; Byun, D.-S.; Nasser, S.; Murray, L.B.; Ayyanar, K.; Arango, D.; Figueroa, M.; Melnick, A.; Kao, G.D.; Augustlicht, L.H. HDAC4 Promotes Growth of Colon Cancer Cells via Repression of P21. *Mot. Biol. Cell 2008, 19, 4062–4075. [CrossRef] [PubMed]

118. Park, J.-H.; Kim, S.-H.; Choi, M.-C.; Lee, J.; Oh, D.-Y.; Im, S.-A.; Bang, Y.-J.; Kim, T.Y. Class II Histone Deacetylases Play Pivotal Roles in Heat Shock Protein 90-Mediated Proteasomal Degradation of Vascular Endothelial Growth Factor Receptors. *Biochem. Biophys. Res. Commun.* 2008, 368, 318–322. [CrossRef] [PubMed]

119. Yeung, F.; Hoberg, J.E.; Ramsey, C.S.; Keller, M.D.; Jones, D.R.; Frye, R.A.; Mayo, M.W. Modulation of NF-κB-Dependent Transcription and Cell Survival by the SIRT1 Deacetylase. *EMBO J.* 2004, 23, 2569–2580. [CrossRef]

120. Kuzmichev, A.; Margueron, R.; Vaquero, A.; Preissner, T.S.; Scher, M.; Kirmizis, A.; Ouyang, X.; Brockdorff, N.; Abate-Shen, C.; Fampham, P. Composition and Histone Substrates of Polycrumb Repressive Group Complexes Change during Cellular Differentiation. *Proc. Natl. Acad. Sci. USA* 2005, 102, 1859–1864. [CrossRef] [PubMed]
121. Cheng, H.-L.; Mostoslavsky, R.; Saito, S.; Manis, J.P.; Gu, Y.; Patel, P.; Bronson, R.; Appella, E.; Alt, F.W.; Chua, K.F. Developmental Defects and P53 Hyperacetylation in Sir2 Homolog (SIRT1)-Deficient Mice. *Proc. Natl. Acad. Sci. USA* 2003, 100, 10794–10799. [CrossRef]

122. McBurney, M.W.; Yang, X.; Jardine, K.; Hixon, M.; Boekelheide, K.; Webb, J.R.; Lansdorp, P.M.; Lemieux, M. The Mammalian SIR2a Protein Has a Role in Embryogenesis and Gametogenesis. *Mol. Cell. Biol.* 2003, 23, 38–54. [CrossRef] [PubMed]

123. Wang, R.-H.; Sengupta, K.; Li, C.; Kim, H.-S.; Cao, L.; Xiao, C.; Kim, S.; Xu, X.; Zheng, Y.; Chilton, B. Impaired DNA Damage Response, Genome Instability, and Tumorigenesis in SIRT1 Mutant Mice. *Cancer Cell* 2008, 14, 312–323. [CrossRef] [PubMed]

124. Saunders, L.R.; Verdin, E. Sirtuins: Critical Regulators at the Crossroads between Cancer and Aging. *Oncogene* 2007, 26, 5489–5504. [CrossRef] [PubMed]

125. Hiratsuka, M.; Inoue, T.; Toda, T.; Kimura, N.; Shirayoshi, Y.; Kamitani, H.; Watanabe, T.; Ohama, E.; Tahimic, C.G.; Kurimasa, A. Proteomics-Based Identification of Differentially Expressed Genes in Human Gliomas: Down-Regulation of SIRT2 Gene. *Biochim. Biophys. Res. Commun.* 2003, 309, 558–566. [CrossRef]

126. Michan, S.; Sinclair, D. Sirtuins in Mammals: Insights into Their Biological Function. *Biochem. J.* 2007, 404, 1–13. [CrossRef]

127. Lee, Y.-S.; Lim, K.-H.; Guo, X.; Kawaguchi, Y.; Gao, Y.; Barrientos, T.; Ordentlich, P.; Wang, X.-F.; Counter, C.M.; Yao, T.-P. The Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic Tumorigenesis. *Cancer Res.* 2008, 68, 7561–7569. [CrossRef]

128. Mottet, D.; Piette, S.; Lamour, V.; Hagedorn, M.; Javerzat, S.; Bikfalvi, A.; Bellahcene, A.; Verdin, E.; Castronovo, V. HDAC4 Represses P21 WAF1/Cip1 Expression in Human Cancer Cells through a Sp1-Dependent, P53-Independent Mechanism. *Onco gene* 2009, 28, 243–256. [CrossRef]

129. Senese, S.; Zaragoza, K.; Minardi, S.; Muradore, I.; Ronzoni, S.; Passafaro, A.; Bernard, L.; Draetta, G.F.; Alcalay, M.; Seiser, C. Role of Histone Deacetylase 1 in Human Tumor Cell Proliferation. *Mol. Cell. Biol.* 2007, 27, 4784–4795. [CrossRef]

130. Draney, C.; Austin, M.C.; Leifer, A.H.; Smith, C.J.; Kener, K.B.; Aiitken, T.J.; Hess, K.H.; Haines, A.C.; Lett, L.A.; Hernandez-Carretero, A. HDAC1 Overexpression Enhances β-Cell Proliferation by down-Regulating Cdkn1b/P27. *Biochem. J.* 2018, 475, 3997–4010. [CrossRef]

131. Zhao, H.; Wang, Y.; Yang, C.; Zhou, J.; Wang, L.; Yi, K.; Li, Y.; Shi, J.; Kang, C.; Zeng, L. EGFR-VIII Downregulated H2AZK4/7AC Though the PI3K/AKT-HDAC2 Axis to Regulate Cell Cycle Progression. *Clin. Transl. Med.* 2020, 9, 10. [CrossRef]

132. Wei, D.; Lu, T.; Ma, D.; Yu, K.; Zhang, T.; Xiong, J.; Wang, W.; Zhang, Z.; Fang, Q.; Wang, J. Synergetic Activity of Imatinib and AR-42 against Chronic Myeloid Leukemia Cells Mainly through HDAC1 Inhibition. *Life Sci.* 2018, 211, 224–237. [CrossRef]

133. Jiang, Y.; Hsieh, J. HDAC3 Controls Gap 2/Mitosis Progression in Adult Neural Stem/Progenitor Cells by Regulating CDK1. *Life Sci.* 2019, 227, 345, 224–237. [CrossRef]

134. Liu, D.-L.; Lu, L.-L.; Dong, L.-L.; Liu, Y.; Ban, X.-Y.; Lian, B.-F.; Xie, L.; Wen, D.; Gao, D.-M.; Ke, A.-W. MiR-17-5p and MiR-20a-5p Suppress Postoperative Metastasis of Hepatocellular Carcinoma via Blocking HGF/ERBB3-NF-KB Positive Feedback Loop. *Theranostics* 2020, 10, 3668–3683. [CrossRef]

135. Yang, J.; Li, B.; Zhao, S.; Du, H.; Du, Y. Exosomal MiR-638 Inhibits Hepatocellular Carcinoma Progression by Targeting SP1. *Onco Targets Ther.* 2020, 13, 6709–6720. [CrossRef]

136. Chen, M.-K.; Cai, M.-Y.; Luo, R.-Z.; Tian, X.; Liao, Q.-M.; Zhang, X.-Y.; Han, J.-D. Overexpression of P53 Correlates with Poor Prognosis in Patients with Cutaneous Squamous Cell Carcinoma. *Br. J. Dermatol.* 2015, 172, 111–119. [CrossRef] [PubMed]

137. Lin, J.; Liu, Z.; Liao, S.; Li, E.; Wu, X.; Zeng, W. Elevated MicroRNA-7 Inhibits Proliferation and Tumor Angiogenesis and Promotes Apoptosis of Gastric Cancer Cells through P53. *Clin. Cell. Cycle* 2020, 19, 2496–2508. [CrossRef]

138. Leslie, P.L.; Chao, Y.L.; Tsai, Y.-H.; Ghosh, S.K.; Porrello, A.; Van Swearingen, A.E.; Harrison, E.B.; Cooley, B.C.; Parker, J.S.; Carey, L.A. Histone Deacetylase 1 Inhibitor Promotes Breast Cancer Metastasis from Lymph Nodes. *Nat. Commun.* 2019, 10, 4192. [CrossRef] [PubMed]

139. Patra, S.; Panigrahi, D.P.; Praharaj, P.P.; Bhol, C.S.; Mahapatra, K.K.; Mishra, S.R.; Behera, B.P.; Jena, M.; Bhutia, S.K. Dysregulation of Histone Deacetylases in Carcinogenesis and Tumor Progression: A Possible Link to Apoptosis and Autophagy. *Cell. Mol. Life Sci.* 2019, 76, 3263–3282. [CrossRef] [PubMed]

140. Atsumi, A.; Tomita, A.; Kiyoi, H.; Naoe, T. Histone Deacetylase 3 (HDAC3) Is Recruited to Target Promoters by PML-RARα as a Component of the N-CoR Co-Repressor Complex to Repress Transcription in Vivo. *Biochem. Biophys. Res. Commun.* 2006, 345, 1471–1480. [CrossRef]

141. Chaucerreau, A.; Mathieu, M.; de Saintignon, J.; Ferreira, R.; Pritchard, L.L.; Mishal, Z.; Dejean, A.; Harel-Bellan, A. HDAC4 Mediates Transcriptional Repression by the Acute Promyelocytic Leukaemia-Associated Protein PLZF. *Oncogene* 2004, 23, 8777–8784. [CrossRef]

142. Wang, J.; Hoshino, T.; Redner, R.L.; Kajigaya, S.; Liu, J.M. ETO, Fusion Partner in t (8; 21) Acute Myeloid Leukemia, Represses Transcription by Interaction with the Human N-CoR/MSin3/HDAC1 Complex. *Proc. Natl. Acad. Sci. USA* 1998, 95, 10860–10865. [CrossRef] [PubMed]

143. Amann, J.M.; Nip, J.; Strom, D.K.; Lutterbach, B.; Harada, H.; Lenny, N.; Downing, J.R.; Meyers, S.; Hiebert, S.W. ETO, a Target of t (8; 21) in Acute Leukemia, Makes Distinct Contacts with Multiple Histone Deacetylases and Binds MSin3A through Its Oligomerization Domain. *Mol. Cell. Biol.* 2001, 21, 6470–6483. [CrossRef] [PubMed]

144. Oehme, I.; Deubzer, H.E.; Wegener, D.; Pickert, D.; Linke, J.-P.; Hero, B.; Kopp-Schneider, A.; Westermann, F.; Ulrich, S.M.; Von Deimling, A. Histone Deacetylase 8 in Neuroblastoma Tumorigenesis. *Clin. Cancer Res.* 2009, 15, 91–99. [CrossRef] [PubMed]
Hrgovic, I.; Doll, M.; Pinter, A.; Kaufmann, R.; Kippenberger, S.; Meissner, M. Histone Deacetylase Inhibitors Interfere with DNA-Damage Response to Promote DNA Nonhomologous End-Joining. Nat. Struct. Mol. Biol. 2010, 17, 1144–1151. [CrossRef]

Nishimoto, K.; Niida, H.; Uchida, C.; Ohhata, T.; Kitagawa, K.; Motegi, A.; Suda, T.; Kitagawa, M. HDAC3 Is Required for XPC Recruitment and Nucleotide Excision Repair of DNA Damage Induced by UV Irradiation. Mol. Cancer Res. 2020, 18, 1367–1378. [CrossRef]

Liu, X.; Wang, Y.; Zhang, R.; Jin, T.; Qu, L.; Jin, Q.; Zheng, J.; Sun, J.; Wu, Z.; Wang, L. HDAC10 Is Positively Associated with PD-L1 Expression and Poor Prognosis in Patients with NSCLC. Front. Oncol. 2020, 10, 485. [CrossRef]

Yang, W.-C.; Bao, H.-Y.; Liu, Y.-Y.; Nie, Y.-Y.; Yang, J.-M.; Hong, P.-Z.; Zhang, Y. Depsidone Derivatives and a Cyclopeptide Produced by Marine Fungus Aspergillus Unguis under Chemical Induction and by Its Plasma Induced Mutant. Molecules 2018, 23, 2245. [CrossRef]

Zhang, M.; Xiang, S.; Joo, H.-Y.; Wang, L.; Williams, K.A.; Liu, W.; Hu, C.; Tong, D.; Haakenson, J.; Wang, C. HDAC6 Deacetylates and Ubiquitinates MSH2 to Maintain Proper Levels of MutSα. Mol. Cell 2014, 55, 31–46. [CrossRef]

Lagunas-Rangel, F.A. Current Role of Mammalian Sirtuins in DNA Repair. DNA Repair 2019, 80, 85–92. [CrossRef]

Luo, J.; Nikolaev, A.Y.; Imai, S.; Chen, D.; Su, F.; Shiloh, A.; Guarente, L.; Gu, W. Negative Control of P53 by Sirt2 Promotes Cell Survival under Stress. Cell 2001, 107, 137–148. [CrossRef]

Mao, Z.; Hine, C.; Tian, X.; Van Meter, M.; Au, M.; Vaidya, A.; Seluanov, A.; Gorbonova, V. SIRT6 Promotes DNA Repair under Stress by Activating PARP1. Science 2011, 332, 1443–1446. [CrossRef] [PubMed]

Van Meter, M.; Simon, M.; Tombline, G.; May, A.; Morello, T.D.; Hubbard, B.P.; Bredbenner, K.; Park, R.; Sinclair, D.A.; Bohr, V.A. JNK Phosphorylates SIRT6 to Stimulate DNA Double-Strand Break Repair in Response to Oxidative Stress by Recruiting PARP1 to DNA Breaks. Cell Rep. 2016, 16, 2641–2650. [CrossRef] [PubMed]

Zhang, H.; Chen, S.; Jia, X.; Huang, Y.; Ji, R.; Zhao, L. Comparison of the Phytotoxicity between Chemically and Green Synthesized Silver Nanoparticles. Sci. Total Environ. 2021, 752, 142264. [CrossRef]

Moustakas, A.; Heldin, C.-H. Signaling Networks Guiding Epithelial–Mesenchymal Transitions during Embryogenesis and Cancer Progression. Cancer Sci. 2007, 98, 1512–1520. [CrossRef]

Pathania, R.; Ramachandran, S.; Mariappan, G.; Thakur, P.; Shi, H.; Choi, J.-H.; Manicassamy, S.; Kolhe, R.; Prasad, P.D.; Sharma, S. Combined Inhibition of DNMT and HDAC Blocks the Tumorigenicity of Cancer Stem-like Cells and Attenuates Mammary Tumor Growth. Cancer Res. 2016, 76, 3224–3235. [CrossRef]

Li, W.; Ding, X.; Wang, S.; Xu, L.; Yin, T.; Han, S.; Geng, J.; Sun, W. Downregulation of Serum Exosomal MiR-320d Predicts Poor Prognosis in Hepatocellular Carcinoma. J. Clin. Lab. Anal. 2020, 34, e23239. [CrossRef]

Byles, V.; Zhu, L.; Lovasa, J.D.; Chmulewski, L.K.; Wang, J.; Faller, D.V.; Dai, Y. SIRT1 Induces EMT by Cooperating with EMT Transcription Factors to Enhance Prostate Cancer Cell Migration and Metastasis. Oncogene 2012, 31, 4619–4629. [CrossRef]

Cheng, X.; Hung, M.-C. Breast Cancer Brain Metastases. Cancer Metastasis Rev. 2007, 26, 635–643. [CrossRef]

Zhou, J.; Li, W.; Guo, J.; Li, G.; Chen, F.; Zhou, J. Downregulation of MiR-329 Promotes Cell Invasion by Regulating BRD4 and Predicts Poor Prognosis in Hepatocellular Carcinoma. Tumor Biol. 2016, 37, 3561–3569. [CrossRef]

Ma, X.; Ezzeldin, H.H.; Diasio, R.B. Histone Deacetylase Inhibitors. Drugs 2009, 69, 1911–1934. [CrossRef] [PubMed]

Lee, J.-Y.; Nagano, Y.; Taylor, J.P.; Lim, K.L.; Yao, T.-P. Disease-Causing Mutations in Parkin Impair Mitochondrial Ubiquitination, Aggregation, and HDAC6-Dependent Mitophagy. J. Cell Biol. 2010, 189, 671–679. [CrossRef] [PubMed]

Peinado, H.; Olmeda, D.; Cano, A. Snail, Zeb and BHLH Factors in Tumour Progression: An Alliance against the Epithelial Phenotype? Nat. Rev. Cancer 2007, 7, 415–428. [CrossRef] [PubMed]

von Burstin, J.; Eser, S.; Paul, M.C.; Seidler, B.; Brandl, M.; Messer, M.; von Werder, A.; Schmidt, A.; Mages, J.; Pagel, P. E-Cadherin Regulates Metastasis of Pancreatic Cancer in Vivo and Is Suppressed by a SNAIL/HDAC1/HDAC2 Repressor Complex. Gastroenterology 2009, 137, 361–371. [CrossRef]

Carmeliti, P. Angiogenesis in Life, Disease and Medicine. Nature 2005, 438, 932–936. [CrossRef]

Moehler, T.; Neben, K.; Ho, A.; Goldschmidt, H. Angiogenesis in Hematologic Malignancies. Ann. Hematol. 2001, 80, 695–705. [CrossRef]

Kim, M.S.; Kwon, H.J.; Lee, Y.M.; Baek, J.H.; Jang, J.-E.; Lee, S.-W.; Moon, E.-J.; Kim, H.-S.; Lee, S.-K.; Chung, H.Y. Histone Deacetylases Induce Angiogenesis by Negative Regulation of Tumor Suppressor Genes. Nat. Med. 2001, 7, 437–443. [CrossRef]

Hrgovic, I.; Doll, M.; Pinter, A.; Kaufmann, R.; Kippenberger, S.; Meissner, M. Histone Deacetylase Inhibitors Interfere with Angiogenesis by Decreasing Endothelial VEGFR-2 Protein Half-Life in Part via a VE-Cadherin-Dependent Mechanism. Exp. Dermatol. 2017, 26, 194–201. [CrossRef]

Schoepflin, Z.R.; Shapiro, I.M.; Risbud, M.V. Class I and IIa HDACs Mediate HIF-1α Stability Through PHD2-Dependent Mechanism, While HDAC6, a Class Ib Member, Promotes HIF-1α Transcriptional Activity in Nucleus Pulposus Cells of the Intervertebral Disc. J. Bone Miner. Res. 2016, 31, 1287–1299. [CrossRef]

Urbich, C.; Rössig, L.; Kalzu, D.; Potente, M.; Boeckel, J.-N.; Knaus, A.; Diehl, F.; Geng, J.-G.; Hofmann, W.-K.; Zeiher, A.M. HDAC5 Is a Repressor of Angiogenesis and Determines the Angiogenic Gene Expression Pattern of Endothelial Cells. Blood J. Am. Soc. Hematol. 2009, 113, 5669–5679. [CrossRef]
172. Tsou, P.-S.; Khanna, D.; Sawalha, A.H. Identification of Cysteine-Rich Angiogenic Inducer 61 as a Potential Antifibrotic and Proangiogenic Mediator in Scleroderma. *Arthritis Rheumatol.* 2019, 71, 1350–1359. [CrossRef] [PubMed]

173. Kaluza, D.; Kroll, J.; Gesierich, S.; Yao, T.-P.; Boon, R.A.; Hergenreider, E.; Tjwa, M.; Rössig, L.; Seto, E.; Augustin, H.G. Class IIb HDAC6 Regulates Endothelial Cell Migration and Angiogenesis by Deacetylation of Contactin. *EMBO J.* 2011, 30, 4142–4156. [CrossRef] [PubMed]

174. Cecconi, F.; Levine, B. The Role of Autophagy in Mammalian Development: Cell Makeover Rather than Cell Death. *Dev. Cell* 2008, 15, 344–357. [CrossRef] [PubMed]

175. Degenhardt, K.; Mathew, R.; Beaudoin, B.; Bray, K.; Anderson, D.; Chen, G.; Mukherjee, C.; Shi, Y.; Gélinas, C.; Fan, Y. Autophagy Promotes Tumor Cell Survival and Restricts Necrosis, Inflammation, and Tumorigenesis. *Cancer Cell* 2006, 10, 51–64. [CrossRef]

176. Moresi, V.; Carrer, M.; Grueter, C.E.; Rifki, O.F.; Shelton, J.M.; Richardson, J.A.; Bassel-Duby, R.; Olson, E.N. Histone Deacetylases 1 and 2 Regulate Autophagy Flux and Skeletal Muscle Homeostasis in Mice. *Proc. Natl. Acad. Sci. USA* 2012, 109, 1649–1654.

177. Majora, M.; Sondenheimer, K.; Knechten, M.; Uthe, I.; Esser, C.; Schiavi, A.; Ventura, N.; Krtummann, J. HDAC Inhibition Improves Autophagic and Lysosomal Function to Prevent Loss of Subcutaneous Fat in a Mouse Model of Cockayne Syndrome. *Sci. Transl. Med.* 2018, 10, eaam7510. [CrossRef]

178. Yang, X.-J.; Seto, E. The Rpd3/Hda1 Family of Lysine Deacetylases: From Bacteria and Yeast to Mice and Men. *Nat. Rev. Mol. Cell Biol.* 2008, 9, 206–218. [CrossRef]

179. Lee, K.J.; Lee, K.Y.; Lee, Y.M. Downregulation of a Tumor Suppressor RECK by Hypoxia through Recruitment of HDAC1 and HIF-1α to Reverse HRE Site in the Promoter. *Biochim. Biophys. Acta (BBA)-Mol. Cell Res.* 2010, 1803, 608–616. [CrossRef]

180. Oehme, I.; Linke, J.-P.; Böck, B.C.; Milde, T.; Lodrini, M.; Hartenstein, B.; Wiegand, I.; Eckert, C.; Roth, W.; Kool, M. Histone Deacetylase 10 Promotes Autophagy-Mediated Cell Survival. *Proc. Natl. Acad. Sci. USA* 2013, 110, E2592–E2601. [CrossRef]

181. Garva, R.; Thepmalee, C.; Yasamut, U.; Sudsaward, S.; Guazzelli, A.; Rajendran, R.; Tongmuang, N.; Khunchai, S.; Meyiami, P.; Limjindaporn, T. Sirtuin Family Members Selectively Regulate Autophagy in Osteosarcoma and Mesotheloma Cells in Response to Cellular Stress. *Front. Oncol.* 2019, 9, 949. [CrossRef]

182. Huang, R.; Xu, Y.; Wan, W.; Shou, X.; Qian, J.; You, Z.; Liu, B.; Chang, C.; Zhou, T.; Lippincott-Schwartz, J. Deacetylation of Nuclear LCP Drives Autophagy Initiation under starvation. *Mol. Cell* 2015, 57, 456–466. [CrossRef] [PubMed]

183. Ou, X.; Lee, M.R.; Huang, X.; Messina-Graham, S.; Bromley, H.E. SIRT1 Positively Regulates Autophagy and Mitochondria Function in Embryonic Stem Cells under Oxidative Stress. *Stem Cells 2014*, 32, 1183–1194. [CrossRef] [PubMed]

184. Polletta, L.; Vernucci, E.; Carnevale, I.; Arcangeli, T.; Rotili, D.; Palmerio, S.; Nowak, T.; Schutkowski, M.; Pellegrini, L. SIRT5 Regulation of Ammonia-Induced Autophagy and Mitophagy. *Autophagy* 2015, 11, 253–270. [CrossRef] [PubMed]

185. Shi, L.; Yan, H.; An, S.; Shen, M.; Jia, W.; Zhang, R.; Zhao, L.; Huang, G.; Liu, J. SIRT5-Mediated Deacetylation of LDHB Promotes Autophagy and Tumorigenesis in Colorectal Cancer. *Mol. Oncol.* 2019, 13, 358–375. [CrossRef] [PubMed]

186. Guo, J.; Wang, Z.; Wu, J.; Liu, M.; Li, M.; Sun, Y.; Huang, W.; Li, Y.; Zhang, Y.; Tang, W. Endothelial SIRT6 Is Vital to Prevent Hypertension and Associated Cardiorenal Injury through Targeting Nkx3. 2-GATA5 Signaling. *Circ. Res.* 2019, 124, 1448–1461. [CrossRef]

187. Moseley, V.R.; Morris, J.; Knackstedt, R.W.; Wargovich, M.J. Green Tea Polyphenol Epigallocatechin-3-Gallate, Contributes to the Degradation of DNMT3A and HDAC3 in HCT 16 Human Colon Cancer Cells. *Anticancer. Res.* 2013, 33, 5325–5333.

188. Groh, I.A.M.; Chen, C.; Lüské, C.; Cartus, A.T.; Esselein, M. Plant Polyphenols and Oxidative Metabolites of the Herbal Alkenylbenzene Methylugenol Suppress Histone Deacetylase Activity in Human Colon Carcinoma Cells. *J. Nutr. Metab.* 2013, 2013, 821082. [CrossRef]

189. Meeran, S.M.; Patel, S.N.; Chan, T.-H.; Tollesbøl, T.O. A Novel Prodrug of Epigallocatechin-3-Gallate: Differential Epigenetic HERT2 Repression in Human Breast Cancer Cells. *Cancer Prev. Res.* 2011, 4, 1243–1254. [CrossRef]

190. Nandakumar, V.; Vaid, M.; Katiyar, S.K. (−)-Epigallocatechin-3-Gallate Reactivates Silenced Tumor Suppressor Genes, Cip1/P21 and P16INK4a, by Reducing DNA Methylation and Increasing Histones Acetylation in Human Skin Cancer Cells. *Carcinogenesis* 2011, 32, 537–544. [CrossRef]

191. Ciesielski, O.; Biesiekierska, M.; Balcerzyk, A. Epigallocatechin-3-Gallate (EGCG) Alters Histone Acetylation and Methylation and Impacts Chromatin Architecture Profile in Human Endothelial Cells. *Molecules 2020*, 25, 2326. [CrossRef]

192. Pandey, M.; Kaur, P.; Shukla, S.; Abbas, A.; Fu, P.; Gupta, S. Plant Flavone Apigenin Inhibits HDAC and Remodels Chromatin to Induce Growth Arrest and Apoptosis in Human Prostate Cancer Cells: In Vitro and in Vivo Study. *Mol. Carcinog.* 2012, 51, 952–962. [CrossRef] [PubMed]

193. Tseng, T.-H.; Chien, M.-H.; Lin, W.-L.; Wen, Y.-C.; Chow, J.-M.; Chen, C.-K.; Kuo, T.-C.; Lee, W.-J. Inhibition of MDA-MB-231 Breast Cancer Cell Proliferation and Tumor Growth by Apigenin through Induction of G2/M Arrest and Histone H3 Acetylation-Mediated P21 WAF1/CIP1 Expression: APIGENIN INHIBITS MDA-MB-231 BREAST CANCER CELL. *Environ. Toxicol.* 2017, 32, 434–444. [CrossRef] [PubMed]

194. Zeng, H.; Huang, P.; Wang, X.; Wu, J.; Wu, M.; Huang, J. Galangin-Induced down-Regulation of BACE1 by Epigenetic Mechanisms in SH-SY5Y Cells. *Neuroscience* 2015, 294, 172–181. [CrossRef] [PubMed]

195. Fang, M.Z.; Chen, D.; Sun, Y.; Jin, Z.; Christman, J.K.; Yang, C.S. Reversal of Hypermethylation and Reactivation of P16INK4a, RARβ, and MGMT Genes by Genistein and Other Isoflavones from Soy. *Clin. Cancer Res.* 2005, 11, 7033–7041. [CrossRef] [PubMed]
196. Majid, S.; Dar, A.A.; Shahryari, V.; Hirata, H.; Ahmad, A.; Saini, S.; Tanaka, Y.; Dahiya, A.V.; Dahiya, R. Genistein Reverses Hypermethylation and Induces Active Histone Modifications in Tumor Suppressor Gene B-Cell Translocation Gene 3 in Prostate Cancer. *Cancer* **2009**, *116*, 66–76. [CrossRef] [PubMed]

197. Li, Y.; Meeran, S.M.; Patel, S.N.; Chen, H.; Hardy, T.M.; Tollefsbol, T.O. Epigenetic Reactivation of Estrogen Receptor-α (ERα) by Genistein Enhances Hormonal Therapy Sensitivity in ERα-Negative Breast Cancer. *Mol. Cancer* **2013**, *12*, 9. [CrossRef]

198. Zhang, Y.; Li, Q.; Chen, H. DNA Methylation and Histone Modifications of Wnt Genes by Genistein during Colon Cancer Development. *Carcinogenesis* **2013**, *34*, 1756–1763. [CrossRef]

199. Kedhari Sundaram, M.; Hussain, A.; Haque, S.; Raina, R.; Afroz, N. Quercetin Modifies 5'-CpG Promoter Methylation and Reactivates Various Tumor Suppressor Genes by Mediating Epigenic Markings in Human Cervical Cancer Cells. *J. Cell. Biochem.* **2019**, *120*, 18357–18369. [CrossRef] [PubMed]

200. Anestopoulos, I.; Sfakianos, A.; Franco, R.; Chlichlia, K.; Panayiotidis, M.; Kroll, D.; Pappa, A. A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma. *Molecules* **2016**, *22*, 62. [CrossRef]

201. Berger, A.; Venturelli, S.; Kallnischkies, M.; Böcker, A.; Busch, C.; Weiland, T.; Noor, S.; Leischner, C.; Weiss, T.S.; Lauer, U.M.; et al. Kaempferol, a New Nutrition-Derived Pan-Inhibitor of Human Histone Deacetylases. *J. Nutr. Biochem.* **2013**, *24*, 977–985. [CrossRef]

202. Lee, W.-J.; Chen, Y.-R.; Tseng, T.-H. Quercetin Induces FasL-Related Apoptosis, in Part, through Promotion of Histone H3 Acetylation in Human Leukemia HL-60 Cells. *Onco. Rep.* **2011**, *25*, 583–591. [PubMed]

203. Kedhari Sundaram, M.; Hussain, A.; Haque, S.; Raina, R.; Afroz, N. Quercetin Modifies 5'-CpG Promoter Methylation and Reactivates Various Tumor Suppressor Genes by Mediating Epigenic Markings in Human Cervical Cancer Cells. *J. Cell. Biochem.* **2019**, *120*, 18357–18369. [CrossRef] [PubMed]

204. Mirza, S.; Sharma, G.; Parshad, R.; Gupta, S.D.; Pandya, P.; Ralhan, R. Expression of DNA Methyltransferases in Breast Cancer Patients and to Analyze the Effect of Natural Compounds on DNA Methyltransferases and Associated Proteins. *J. Breast Cancer* **2013**, *16*, 23–31. [CrossRef] [PubMed]

205. Deb, G.; Thakur, V.S.; Limaye, A.M.; Gupta, S. Epigenetic Induction of Tissue Inhibitor of Matrix Metalloproteinase-3 by Green Tea Polyphenols in Breast Cancer Cells. *Mol. Carcinog.* **2015**, *54*, 485–499. [CrossRef] [PubMed]

206. Saldanha, S.N.; Kala, R.; Tollefsbol, T.O. Molecular Mechanisms for Inhibition of Colon Cancer Cells by Combined Epigenetic-Modulating Epigallocatechin Gallate and Sodium Butyrate. *Exp. Cell Res.* **2014**, *324*, 40–53. [CrossRef] [PubMed]

207. Khan, M.A.; Hussain, A.; Sundaram, M.K.; Alalumi, U.; Gunasekera, D.; Ramesh, L.; Hamza, A.; Quraishi, U. (–)-Epigallocatechin-3-Gallate Reverses the Expression of Various Tumor-Suppressor Genes by Inhibiting DNA Methyltransferases and Histone Deacetylases in Human Cervical Cancer Cells. *Onco. Rep.* **2015**, *33*, 1976–1984. [CrossRef] [PubMed]

208. Zhang, Y.; Wang, X.; Han, L.; Zhou, Y.; Sun, S. Green Tea Polyphenol EGCG Reverse Cisplatin Resistance of A549/DDP Cell Line through Candidate Genes Demethylation. *Biomed. Pharmacother.* **2015**, *69*, 285–290. [CrossRef]

209. Borutinskaite, V.; Virkšaitė, G.; Gudelytė, G.; Navakauskienė, R. Green Tea Polyphenol EGCG Causes Anti-Cancerous Epigenetic Modulations in Acute Promyelocytic Leukemia Cells. *Leuk. Lymphoma* **2018**, *59*, 469–478. [CrossRef]

210. Deb, G.; Shankar, E.; Thakur, V.S.; Ponsky, L.; Bodner, D.R.; Fu, P.; Gupta, S. Green Tea-Induced Epigenetic Reactivation of Tissue Inhibitor of Matrix Metalloproteinase-3 Suppresses Prostate Cancer Progression through Histone-Modifying Enzymes. *Mol. Carcinog.* **2019**, *58*, 1194–1207. [CrossRef]

211. Steed, K.L.; Jordan, H.R.; Tollefsbol, T.O. SAHA and ECGG Promote Apoptosis in Triple-Negative Breast Cancer Cells, Possibly Through the Modulation of CIAP2. *Anticancer Res.* **2020**, *40*, 9–26. [CrossRef]

212. Kuo, H.-C.D.; Wu, R.; Li, S.; Yang, A.Y.; Kong, A.-N. Anthocyanin Delphinidin Prevents Neoplastic Transformation of Mouse Skin JB6 P+ Cells: Epigenetic Re-Activation of Nrf2-ARE Pathway. *AAPS J.* **2019**, *21*, 83. [CrossRef] [PubMed]

213. Paredes-Gonzalez, X.; Fuentes, F.; Su, Z.-Y.; Kong, A.-N.T. Apigenin Reactivates Nrf2 Anti-Oxidative Stress Signaling in Mouse Skin Epidermal JB6 P+ Cells Through Epigenetics Modifications. *AAPS J.* **2014**, *16*, 727–735. [CrossRef] [PubMed]

214. Paul, B.; Li, Y.; Tollefsbol, T. The Effects of Combinatorial Genistein and Sulforaphane in Breast Tumor Inhibition: Role in Epigenetic Regulation. *Int. J. Mol. Sci.* **2018**, *19*, 1754. [CrossRef] [PubMed]

215. Sundaram, M.; Mz, A.; Aa, M. Genistein Induces Alterations of Epigenetic Modulatory Signatures in Human Cervical Cancer Cells. *Anticancer Agents Med. Chem.* **2018**, *18*, 412–421. [CrossRef]

216. Attoub, S.; Hassam, A.H.; Vanhoecke, B.; Iratni, R.; Takahashi, T.; Gab, A.-M.; Bracke, M.; Awad, S.; John, A.; Kamalboor, H.A.; et al. Inhibition of Cell Survival, Invasion, Tumor Growth and Histone Deacetylation Activity by the Dietary Flavonoid Luteolin in Human Epithioidioid Cancer Cells. *Eur. J. Pharmacol.* **2011**, *651*, 18–25. [CrossRef]

217. Zuo, Q.; Wu, R.; Xiao, X.; Yang, C.; Yang, Y.; Wang, C.; Lin, L.; Kong, A. The Dietary Flavone Luteolin Epigenetically Activates the Nrf2 Pathway and Blocks Cell Transformation in Human Colorectal Cancer HCT116 Cells. *J. Cell. Biochem.* **2018**, *119*, 9573–9582. [CrossRef]

218. Zhang, T.; Li, S.; Li, J.; Yin, F.; Hua, Y.; Wang, Z.; Lin, B.; Wang, H.; Zou, D.; Zhou, Z.; et al. Natural Product Pectolinarigenin Inhibits Osteosarcoma Growth and Metastasis via SHP-1-Mediated STAT3 Signaling Inhibition. *Cell Death Dis.* **2016**, *7*, e2421. [CrossRef]

219. Li, S.; Li, W.; Wang, C.; Wu, R.; Yin, R.; Kuo, H.-C.; Wang, L.; Kong, A.-N. Pelargonicin Reduces the TPA Induced Transformation of Mouse Epidermal Cells –Potential Involvement of Nrf2 Promoter Demethylation. *Chem. Biol. Interact.* **2019**, *309*, 108701. [CrossRef]
220. Kauntz, H.; Bousserouel, S.; Gossé, F.; Raul, F. Epigenetic Effects of the Natural Flavonolignan Silibinin on Colon Adenocarcinoma Cells and Their Derived Metastatic Cells. *Oncol. Lett.* **2013**, *5*, 1273–1277. [CrossRef]

221. Kuang, H.; Tang, Z.; Zhang, C.; Wang, Z.; Li, W.; Yang, C.; Wang, Q.; Yang, B.; Kong, A.-N. Taxifolin Activates the Nrf2 Anti-Oxidative Stress Pathway in Mouse Skin Epidermal JB6 P+ Cells through Epigenetic Modifications. *Int. J. Mol. Sci.* **2017**, *18*, 1546. [CrossRef]

222. Priyadarshini, R.V.; Vinothini, G.; Murugan, R.S.; Manikandan, P.; Nagini, S. The Flavonoid Quercetin Modulates the Hallmark Capabilities of Hamster Buccal Pouch Tumors. *Nutr. Cancer* **2011**, *63*, 218–226. [CrossRef] [PubMed]

223. Zheng, N.-G.; Wang, J.-L.; Yang, S.-L.; Wu, J.-L. Aberrant Epigenetic Alteration in Eca9706 Cells Modulated by Nanoliposomal Kondo, M.; MacKinnon, S.L.; Craft, C.C.; Matchett, M.D.; Hurta, R.A.; Neto, C.C. Ursolic Acid and Its Esters: Occurrence in *Food Agric.* **2011**, *91*, 789–796. [CrossRef]

224. Wang, Z.; Liu, Y.; Xue, Y.; Hu, H.; Ye, J.; Li, X.; Lu, Z.; Meng, F.; Liang, S. Berberine Acts as a Putative Epigenetic Modulator by Affecting the Histone Code. *Toxicol. Vitir.* **2016**, *36*, 10–17. [CrossRef] [PubMed]

225. Florean, C.; Schnekenburger, M.; Lee, J.-Y.; Kim, K.R.; Mazumder, A.; Song, S.; Kim, J.-M.; Grandjenette, C.; Kim, J.-G.; Yoon, A.-Y.; et al. Discovery and Characterization of Isofistularin-3, a Marine Brominated Alkaloid, as a New DNA Demethylating Agent Inducing Cell Cycle Arrest and Sensitization to TRAIL in Cancer Cells. *Oncotarget* **2016**, *7*, 24027–24049. [CrossRef] [PubMed]

226. Tiwari, P.; Gupta, K.P. Modulation of MiR-203 and Its Regulators as a Function of Time during the Development of 7, 12 Dimethylbenz[a] Anthracene Induced Mouse Skin Tumors in Presence or Absence of the Antitumor Agents. *Toxicol. Appl. Pharmacol.* **2014**, *278*, 148–158. [CrossRef] [PubMed]

227. Vincent, A.; Ducourouble, M.; Van Seuningen, I. Epigenetic Regulation of the Human Mucin Gene MUC4 in Epithelial Cancer Cell Lines Involves Both DNA Methylation and Histone Modifications Mediated by DNA Methyltransferases and Histone Deacetylases. *FASEB J.* **2008**, *22*, 3035–3045. [CrossRef] [PubMed]

228. Ahn, M.Y.; Jung, J.H.; Na, Y.J.; Kim, H.S. A Natural Histone Deacetylase Inhibitor, Psammaplin A, Induces Cell Cycle Arrest and Apoptosis in Human Endometrial Cancer Cells. *Gynecol. Oncol.* **2008**, *108*, 27–33. [CrossRef] [PubMed]

229. Baud, M.G.J.; Leiser, T.; Haus, P.; Samal, S.; Wong, A.C.; Wood, R.J.; Petrucci, V.; Gunaratnam, M.; Hughes, S.M.; Buluwela, L.; et al. Defining the Mechanism of Action and Enzymatic Selectivity of Psammaplin A against Its Epigenetic Targets. *J. Med. Chem.* **2015**, *58*, 1731–1750. [CrossRef]

230. Piña, I.C.; Gautschi, J.T.; Wang, G.-Y.-S.; Sanders, M.L.; Schmitz, F.J.; France, D.; Cornell-Kennon, S.; Sambucetti, L.C.; Remiszewski, S.W.; Perez, L.B.; et al. Psammaplins from the Sponge *Pseudoceratina p Urpurea*: Inhibition of Both Histone Deacetylation and DNA Methyltransferase. *J. Org. Chem.* **2003**, *68*, 3866–3873. [CrossRef]

231. Meng, F.; Sun, G.; Zhong, M.; Yu, Y.; Brewer, M.A. Inhibition of DNA Methyltransferases, Histone Deacetylases and Lysine-Specific Demethylase-1 Suppresses the Tumorigenicity of the Ovarian Cancer Ascites Cell Line SKOV3. *Int. J. Oncol.* **2013**, *43*, 495–502. [CrossRef]

232. Zhang, C.; Wang, C.; Li, W.; Wu, R.; Guo, Y.; Cheng, D.; Yang, Y.; Androulakis, I.P.; Kong, A.-N. Pharmacokinetics and Pharmacodynamics of the Triterpenoid Ursolic Acid in Regulating the Antioxidant, Anti-Inflammatory, and Epigenetic Gene Responses in Rat Leukocytes. *Toxicol. Appl. Pharmacol.* **2016**, *310*, 204–211. [CrossRef] [PubMed]

233. Shukla, S.; Khan, S.; Kumar, S.; Sinha, S.; Farahan, M.; Bora, H.K.; Maurya, R.; Meean, S.C. Cucurbitacin B Alters the Expression of Tumor-Related Genes by Epigenetic Modifications in NSCLC and Inhibits NNK-Induced Lung Tumorigenesis. *Cancer Prev. Res.* **2015**, *8*, 552–562. [CrossRef] [PubMed]

234. Machado, D.G.; Neis, V.B.; Balen, G.O.; Colla, A.; Cunha, M.P.; Dalmacco, J.B.; Pizzolatti, M.G.; Prediger, R.D.; Rodrigues, A.L.S. Antidepressant-like Effect of Ursolic Acid Isolated from *Rosmarinus officinalis* L. in Mice: Evidence for the Involvement of the Dopaminergic System. *Pharmacol. Biochem. Behav.* **2012**, *103*, 204–211. [CrossRef] [PubMed]

235. Kondo, M.; MacKinnon, S.L.; Craft, C.C.; Matchett, M.D.; Hurta, R.A.; Neto, C.C. Ursolic Acid and Its Esters: Occurrence in Cranberries and Other Vaccinium Fruit and Effects on Metalloproteinase Activity in DU145 Prostate Tumor Cells. *J. Sci. Food Agric.* **2011**, *91*, 789–796. [CrossRef] [PubMed]

236. Gopal, Y.N.V.; Arora, T.S.; Van Dyke, M.W. Parthenolide Specifically Depletes Histone Deacetylase 1 Protein and Induces Cell Death through Ataxia Telangiectasia Mutated. *Chem. Biol.* **2007**, *14*, 813–823. [CrossRef] [PubMed]

237. Dai, Y.; Guzman, M.L.; Chen, S.; Wang, L.; Yeung, S.-K.; Piet, X.-Y.; Dent, P.; Jordan, C.T.; Grant, S. The NF (Nuclear Factor)-KB Inhibitor Parthenolide Interacts with Histone Deacetylase Inhibitors to Induce MKK7/JNK1-Dependent Apoptosis in Human Acute Myeloid Leukaemia Cells: Parthenolide Potentiates HDAC Inhibitor Lethality in AML. *Br. J. Haematol.* **2010**, *151*, 70–83. [CrossRef] [PubMed]

238. Ghantous, A.; Saikali, M.; Rau, T.; Gali-Muhtasib, H.; Schneider-Stock, R.; Darwiche, N. Inhibition of Tumor Promotion by Parthenolide: Epigenetic Modulation of P21. *Cancer Prev. Res.* **2012**, *5*, 1298–1309. [CrossRef]

239. Carlisi, D.; Lauricella, M.; D’Anneo, A.; Butitta, G.; Emanuele, S.; di Fiore, R.; Martinez, R.; Rolfo, C.; Vento, R.; Tesoriere, G. The Synergistic Effect of SAHA and Parthenolide in MDA-MB231 Breast Cancer Cells: THE EFFECT OF PN/SAHA COMBINATION IN MDA-MB231 CELLS. *J. Cell. Physiol.* **2015**, *230*, 1276–1289. [CrossRef]

240. Kim, H.; Ramirez, C.N.; Su, Z.-Y.; Kong, A.-N.T. Epigenetic Modifications of Triterpenoid Ursolic Acid in Activating Nrf2 and Blocking Cellular Transformation of Mouse Epidermal Cells. *J. Nutr. Biochem.* **2016**, *33*, 54–62. [CrossRef]
266. Lee, S.J.; Krauthauser, C.; Maduskuie, V.; Fawcett, P.T.; Olson, J.M.; Rajasekaran, S.A. Curcumin-Induced HDAC Inhibition and Attenuation of Medulloblastoma Growth in Vitro and in Vivo. BMC Cancer 2011, 11, 144. [CrossRef] [PubMed]

267. Shu, L.; Khor, T.O.; Lee, J.-H.; Boyanapalli, S.S.S.; Huang, Y.; Wu, T.-Y.; Saw, C.L.-L.; Cheung, K.-L.; Kong, A.-N.T. Epigenetic CpG Demethylation of the Promoter and Reactivation of the Expression of Neurog1 by Curcumin in Prostate LNCaP Cells. AAPS J. 2011, 13, 606-614. [CrossRef] [PubMed]

268. Lee, M.-J.; Tsai, Y.-J.; Lin, M.-Y.; You, H.-L.; Kalyanam, N.; Ho, C.-T.; Pan, M.-H. Calebin-A Induced Death of Malignant Peripheral Nerve Sheath Tumor Cells by Activation of Histone Acetyltransferase. Phytomedicine 2019, 57, 377-384. [CrossRef] [PubMed]

269. Kala, R.; Shah, H.N.; Martin, S.L.; Tollefsbol, T.O. Epigenetic-Based Combinatorial Resveratrol and Pterostilbene Alters DNA Damage Response by Affecting SIRT1 and DNMT Enzyme Expression, Including SIRT1-Dependent γ-H2AX and Telomerase Regulation in Triple-Negative Breast Cancer. BMC Cancer 2015, 15, 672. [CrossRef]

270. Juli, G.; Oliverio, M.; Bellizzi, D.; Gallo Cantafio, M.E.; Grillone, K.; Passarino, G.; Colica, C.; Nardi, M.; Rossi, M.; Procopio, A.; et al. Anti-Tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma. Cancers 2019, 11, 990. [CrossRef]

271. Kang, I.; Okla, M.; Chung, S. Ellagic Acid Inhibits Adipocyte Differentiation through Coactivator-Associated Arginine Methyltransferase 1-Mediated Chromatin Modification. J. Nutr. Biochem. 2014, 25, 946-953. [CrossRef]

272. Wang, L.; Zhang, C.; Guo, Y.; Su, Z.-Y.; Yang, Y.; Shu, L.; Kong, A.-N.T. Blocking of JB6 Cell Transformation by Tanshinone IIA: Epigenetic Reactivation of Nrf2 Antioxidative Stress Pathway. AAPS J. 2014, 16, 1214-1225. [CrossRef]

273. Liu, D.; Wu, D.; Zhao, L.; Yang, Y.; Ding, J.; Dong, L.; Hu, L.; Wang, F.; Zhao, X.; Cai, Y.; et al. Arsenic Trioxide Reduces Global Histone H4 Acetylation at Lysine 16 through Direct Binding to Histone Acetyltransferase HMOF in Human Cells. PLoS ONE 2015, 10, e0141014. [CrossRef] [PubMed]

274. Peng, Z.; Zhou, W.; Zhang, C.; Liu, H.; Zhang, Y. Curcumol Controls Choriocarcinoma Stem-Like Cells Self-Renewal via Repression of DNA Methyltransferase (DNMT)- and Histone Deacetylase (HDAC)-Mediated Epigenetic Regulation. Mol. Sci. Monit. 2018, 24, 461-472. [CrossRef]

275. Xiang, N.; Zhao, R.; Song, G.; Zhong, W. Selenium Modifies GSTP1 and Histone Methylation and Acetylation in Human Prostate Cancer Cells. AACR J. 2008, 68, 749.

276. Saiko, P.; Pemberger, M.; Horvath, Z.; Savinc, I.; Grusch, M.; Handler, N.; Jaeger, W.; Fritzer-Szekeres, M.; Sze-keres, T. Novel Resveratrol Analogues Induce Apoptosis and Cause Cell Cycle Arrest in HT29 Human Colon Cancer Cells: Inhibition of Ribonucleotide Reductase Activity. Oncol. Rep. 2008, 19, 1621–1626.

277. Koushki, M.; Amiri-Dashatan, N.; Ahmadi, N.; Abbaszadeh, H.-A.; Rezaei-Tavirani, M. Resveratrol: A Miraculous Natural Compound for Diseases Treatment. Food Sci. Nutr. 2018, 6, 2473–2490.

278. Izquierdo-Torres, E.; Hernández-Oliveras, A.; Meneses-Morales, I.; Rodríguez, G.; Fuentes-Garcia, G.; Zarain-Herzberg, Á. Resveratrol Up-Regulates ATP2A3 Gene Expression in Breast Cancer Cell Lines through Epigenetic Mechanisms. Int. J. Biochem. Cell Biol. 2019, 113, 37–47. [CrossRef]

279. Aggarwal, B.B.; Yuan, W.; Li, S.; Gupta, S.C. RCurcumin-Free Turmeric Exhibits Anti-Inflammatory and Anticancer Activities: Identification of Novel Components of Turmeric. Mol. Nutr. Food Res. 2013, 57, 1529–1542.

280. Kala, R.; Tollefsbol, T.O.; Li, Y. Potential of Resveratrol in Inhibiting Cancer and Slowing Aging. J. Nutr. Food Sci. S 2015, 5.

281. Liu, T.; Liu, P.Y.; Marshall, G.M. The Critical Role of the Class III Histone Deacetylase SIRT1 in Cancer. Cancer Res. 2009, 69, 1702–1705.

282. Emadi, A.; Gore, S.D. Arsenic trioxide—An old drug rediscovered. Blood Rev. 2010, 24, 191–199. [CrossRef]

283. Hashem, S.; Nisar, S.; Sageena, G.; Macha, M.A.; Yadav, S.K.; Krishnankutty, R.; Uddin, S.; Harris, M.; Bhat, A.A. Therapeutic Effects of Curcumol in Several Diseases; An Overview. Nutr. Cancer 2021, 73, 181–195. [CrossRef] [PubMed]